Emergent BioSolutions (EBS) 10-Q 11 Dec 23 2023 Q3 Quarterly report Financial data

Cover Page

Cover Page - shares	9 Months Ended
	Sep. 30, 2023	Dec. 01, 2023
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2023
Document Transition Report	false
Entity File Number	001-33137
Entity Registrant Name	EMERGENT BIOSOLUTIONS INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	14-1902018
Entity Address, Address Line One	400 Professional Drive Suite 400
Entity Address, City or Town	Gaithersburg,
Entity Address, State or Province	MD
Entity Address, Postal Zip Code	20879
City Area Code	240
Local Phone Number	631-3200
Title of 12(b) Security	Common Stock, par Value $0.001 per share
Trading Symbol	EBS
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding (in shares)		51,884,398
Entity Central Index Key	0001367644
Current Fiscal Year End Date	--12-31
Amendment Flag	false
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q3

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Millions	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 87.8			$ 642.6	$ 240.9
Accounts receivable, net	216.5			159.2	189.2
Inventories, net	354.1			350.7	528.2
Prepaid expenses and other current assets	62.4			57.9	139.9
Total current assets	720.8			1,210.4	1,098.3
Property, plant and equipment, net	395.4			817.6	806.8
Intangible assets, net	582.8			728.8	724.9
Goodwill	0			218.2	224.9
Other assets	194.1			191.3	40.8
Total assets	1,893.1			3,166.3	2,895.7
Current liabilities:
Accounts payable	112.7			103.5	101
Accrued expenses	17			34.9	35.7
Accrued compensation	82.5			87.3	82.5
Debt, current portion	413.6			957.3	21.2
Other current liabilities	38.2			45.9	24
Total current liabilities	664			1,228.9	264.4
Debt, net of current portion	448.2			448.5	1,032.1
Deferred tax liability	52.4			59.7	113.9
Other liabilities	31.3			41.5	52.3
Total liabilities	1,195.9			1,778.6	1,462.7
Stockholders' equity:
Preferred stock, par value $0.001 per share; 15.0 shares authorized, no shares issued or outstanding	0			0	0
Common stock, par value $0.001 per share; 200.0 shares authorized, 57.4 and 55.7 shares issued; 51.8 and 50.1 shares outstanding, respectively	0.1			0.1	0.1
Treasury stock, at cost, 5.6 and 5.6 common shares, respectively	(227.7)			(227.7)	(227.7)
Additional paid-in capital	899.7			873.5	860.1
Accumulated other comprehensive income (loss), net	(2.6)			3.1	(5.2)
Retained earnings	27.7			738.7	805.7
Total stockholders’ equity	697.2	$ 957.7	$ 1,204.1	1,387.7	1,433	$ 1,508.3	$ 1,566.9	$ 1,611.5
Total liabilities and stockholders’ equity	$ 1,893.1			$ 3,166.3	$ 2,895.7

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021
Stockholders' equity:
Preferred stock, par value (in dollars per share)	$ 0.001			$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	15,000,000			15,000,000	15,000,000
Preferred stock, shares issued (in shares)	0			0	0
Preferred stock, shares outstanding (in shares)	0			0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001	$ 0.001	$ 0.001	$ 0.001	$ 0.001	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	200,000,000			200,000,000	200,000,000
Common stock, shares issued (in shares)	57,400,000			55,700,000	55,500,000
Common stock, shares outstanding (in shares)	51,800,000			50,100,000	49,900,000
Treasury stock (in shares)	5,600,000			5,600,000	5,600,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($) shares in Millions, $ in Millions	3 Months Ended						9 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2023	Sep. 30, 2022
Revenues:
Total revenues	$ 270.5	$ 337.9	$ 164.3	$ 239.9	$ 242.6	$ 304.8	$ 772.7	$ 787.3
Operating expenses:
Cost of goods and services sold	176.8			147.2			520.3	472.6
Goodwill impairment	218.2			0			218.2	0
Impairment of long-lived assets	0			0			306.7	0
Research and development	15.3			42.2			82	141.3
Selling, general and administrative	86			81.8			278.7	246.1
Amortization of intangible assets	16.3			14			49.4	42
Total operating expenses	512.6			285.2			1,455.3	902
Loss from operations	(242.1)	(292.9)	(147.6)	(45.3)	(76.3)	6.9	(682.6)	(114.7)
Other income (expense):
Interest expense	(19.7)			(8.5)			(66.2)	(24.5)
Gain on sale of business	(0.7)			0			74.2	0
Other, net	(3.4)			(13.4)			(2.1)	(18.4)
Total other income (expense), net	(23.8)			(21.9)			5.9	(42.9)
Loss before income taxes	(265.9)			(67.2)			(676.7)	(157.6)
Income tax provision (benefit)	(2.5)			19.9			34.3	(13)
Net loss	$ (263.4)	$ (261.4)	$ (186.2)	$ (87.1)	$ (52.9)	$ (4.6)	$ (711)	$ (144.6)
Net loss per common share
Basic (in dollars per share)	$ (5.08)	$ (5.16)	$ (3.71)	$ (1.75)	$ (1.06)	$ (0.09)	$ (13.97)	$ (2.88)
Diluted (in dollars per share)	$ (5.08)	$ (5.16)	$ (3.71)	$ (1.75)	$ (1.06)	$ (0.09)	$ (13.97)	$ (2.88)
Weighted average shares outstanding
Basic (in shares)	51.8			49.9			50.9	50.2
Diluted (in shares)	51.8			49.9			50.9	50.2
Product sales, net
Revenues:
Services	$ 249.8			$ 186.2			$ 695.4	$ 660.5
Operating expenses:
Cost of goods and services sold	132.5	$ 134.9	$ 101.2	85.2	$ 92.2	$ 79.4	368.6	256.8
CDMO
Revenues:
Total CDMO revenues	14.2			36.3			57.7	92.5
Operating expenses:
Cost of goods and services sold	44.3	$ 55.7	$ 51.7	62	$ 79.8	$ 74	151.7	215.8
Services
Revenues:
Services	13.2			36.1			52.2	87.8
Leases
Revenues:
Leases	1			0.2			5.5	4.7
Contracts and grants
Revenues:
Services	$ 6.5			$ 17.4			$ 19.6	$ 34.3

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Loss - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Statement of Comprehensive Income [Abstract]
Net loss	$ (263.4)	$ (87.1)	$ (711)	$ (144.6)
Other comprehensive income (loss), net of tax:
Foreign currency translation adjustments, net	1.2	(1.3)	3.7	(0.4)
Unrealized gains (losses) on hedging activities	0.9	2.6	(2.3)	9.4
Reclassification adjustment for losses (gains) on hedging activities	(3.1)	(0.4)	(3.6)	1.9
Reclassification adjustment for gains on pension benefit obligation	0	0	(3.5)	0
Total other comprehensive income (loss), net of tax	(1)	0.9	(5.7)	10.9
Comprehensive loss, net of tax	$ (264.4)	$ (86.2)	$ (716.7)	$ (133.7)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Operating Activities
Net loss	$ (711)	$ (144.6)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	19.1	33.4
Long-term incentive plan expense	3.7	0
Depreciation and amortization	95.5	107.6
Change in fair value of contingent obligations, net	(0.4)	2.4
Amortization of deferred financing costs	15.6	3.1
Deferred income taxes	(3.7)	25.5
Gain on sale of travel health business	(74.2)	0
Goodwill impairment	218.2	0
Impairment of long-lived assets	306.7	0
Other	8.9	13
Changes in operating assets and liabilities:
Accounts receivable	(58.5)	82.5
Inventories	(25)	(102.8)
Prepaid expenses and other assets	(18.3)	(34.3)
Accounts payable	17.7	(11.8)
Accrued expenses and other liabilities	(30.2)	(48.4)
Accrued compensation	(0.8)	(5.7)
Income taxes receivable and payable, net	(3.5)	(51)
Contract liabilities	1.8	4.2
Net cash used in operating activities	(238.4)	(126.9)
Investing Activities
Purchases of property, plant and equipment	(40.2)	(92.2)
Asset acquisitions	0	(243.7)
Milestone payment from prior asset acquisition	(6.3)	0
Proceeds from sale of travel health business, net	270.2	0
Net cash provided by (used in) investing activities	223.7	(335.9)
Financing Activities
Purchases of treasury stock	0	(81.9)
Proceeds from revolving credit facility	0	238
Principal payments on revolving credit facility	(386.8)	0
Principal payments on term loan facility	(160.7)	(25.3)
Proceeds from stock-based compensation activity	1.3	3
Taxes paid for stock-based compensation activity	(2.4)	(5.7)
Proceeds from at-the-market sale of stock, net of commissions and expenses	8.2	0
Net cash provided by (used in) financing activities:	(540.4)	128.1
Effect of exchange rate changes on cash, cash equivalents and restricted cash	0.3	(0.6)
Net change in cash, cash equivalents and restricted cash	(554.8)	(335.3)
Cash, cash equivalents and restricted cash, beginning of period	642.6	576.3
Cash, cash equivalents and restricted cash, end of period	87.8	241
Supplemental disclosure of cash flow information:
Cash paid for interest	56.5	26.7
Cash paid for income taxes	38.3	23.9
Supplemental information on non-cash investing and financing activities:
Purchases of property, plant and equipment unpaid at period end	$ 9.2	$ 10

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Changes in Stockholders' Equity - USD ($) $ in Millions	Total	$0.001 Par Value Common Stock	Treasury Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Income (Loss)	Retained Earnings
Beginning balance (in shares) at Dec. 31, 2021		55,100,000
Beginning balance at Dec. 31, 2021	$ 1,611.5	$ 0.1	$ (152.2)	$ 829.4	$ (16.1)	$ 950.3
Beginning balance (in shares) at Dec. 31, 2021			(3,800,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(4.6)					(4.6)
Share-based compensation activity (in shares)		200,000
Share-based compensation activity	5.4			5.4
Repurchases of stock (in shares)			(1,100,000)
Repurchases of common stock	(52.2)		$ (52.2)
Other comprehensive income (loss), net of tax	6.8				6.8
Ending balance (in shares) at Mar. 31, 2022		55,300,000
Ending balance at Mar. 31, 2022	1,566.9	$ 0.1	$ (204.4)	834.8	(9.3)	945.7
Ending balance (in shares) at Mar. 31, 2022			(4,900,000)
Beginning balance (in shares) at Dec. 31, 2021		55,100,000
Beginning balance at Dec. 31, 2021	1,611.5	$ 0.1	$ (152.2)	829.4	(16.1)	950.3
Beginning balance (in shares) at Dec. 31, 2021			(3,800,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(144.6)
Repurchases of stock (in shares)			(1,800,000)
Repurchases of common stock			$ (75.5)
Other comprehensive income (loss), net of tax	$ 10.9
Ending balance (in shares) at Sep. 30, 2022	55,500,000	55,500,000
Ending balance at Sep. 30, 2022	$ 1,433	$ 0.1	$ (227.7)	860.1	(5.2)	805.7
Ending balance (in shares) at Sep. 30, 2022	(5,600,000)		(5,600,000)
Beginning balance (in shares) at Mar. 31, 2022		55,300,000
Beginning balance at Mar. 31, 2022	$ 1,566.9	$ 0.1	$ (204.4)	834.8	(9.3)	945.7
Beginning balance (in shares) at Mar. 31, 2022			(4,900,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(52.9)					(52.9)
Share-based compensation activity (in shares)		200,000
Share-based compensation activity	14.4			14.4
Repurchases of stock (in shares)			(700,000)
Repurchases of common stock	(23.3)		$ (23.3)
Other comprehensive income (loss), net of tax	3.2				3.2
Ending balance (in shares) at Jun. 30, 2022		55,500,000
Ending balance at Jun. 30, 2022	1,508.3	$ 0.1	$ (227.7)	849.2	(6.1)	892.8
Ending balance (in shares) at Jun. 30, 2022			(5,600,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(87.1)					(87.1)
Share-based compensation activity	10.9			10.9
Repurchases of stock (in shares)			0
Other comprehensive income (loss), net of tax	$ 0.9				0.9
Ending balance (in shares) at Sep. 30, 2022	55,500,000	55,500,000
Ending balance at Sep. 30, 2022	$ 1,433	$ 0.1	$ (227.7)	860.1	(5.2)	805.7
Ending balance (in shares) at Sep. 30, 2022	(5,600,000)		(5,600,000)
Beginning balance (in shares) at Dec. 31, 2022	55,700,000	55,700,000
Beginning balance at Dec. 31, 2022	$ 1,387.7	$ 0.1	$ (227.7)	873.5	3.1	738.7
Beginning balance (in shares) at Dec. 31, 2022	(5,600,000)		(5,600,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	$ (186.2)					(186.2)
Share-based compensation activity (in shares)		300,000
Share-based compensation activity	4.7			4.7
Other comprehensive income (loss), net of tax	(2.1)				(2.1)
Ending balance (in shares) at Mar. 31, 2023		56,000,000
Ending balance at Mar. 31, 2023	$ 1,204.1	$ 0.1	$ (227.7)	878.2	1	552.5
Ending balance (in shares) at Mar. 31, 2023			(5,600,000)
Beginning balance (in shares) at Dec. 31, 2022	55,700,000	55,700,000
Beginning balance at Dec. 31, 2022	$ 1,387.7	$ 0.1	$ (227.7)	873.5	3.1	738.7
Beginning balance (in shares) at Dec. 31, 2022	(5,600,000)		(5,600,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	$ (711)
Other comprehensive income (loss), net of tax	$ (5.7)
Ending balance (in shares) at Sep. 30, 2023	57,400,000	57,400,000
Ending balance at Sep. 30, 2023	$ 697.2	$ 0.1	$ (227.7)	899.7	(2.6)	27.7
Ending balance (in shares) at Sep. 30, 2023	(5,600,000)		(5,600,000)
Beginning balance (in shares) at Mar. 31, 2023		56,000,000
Beginning balance at Mar. 31, 2023	$ 1,204.1	$ 0.1	$ (227.7)	878.2	1	552.5
Beginning balance (in shares) at Mar. 31, 2023			(5,600,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(261.4)					(261.4)
Share-based compensation activity (in shares)		300,000
Share-based compensation activity	9.4			9.4
At-the-market sale of stock, net of commissions and expenses (in shares)		1,100,000
At-the-market sale of stock, net of commissions and expenses	8.2			8.2
Other comprehensive income (loss), net of tax	(2.6)				(2.6)
Ending balance (in shares) at Jun. 30, 2023		57,400,000
Ending balance at Jun. 30, 2023	957.7	$ 0.1	$ (227.7)	895.8	(1.6)	291.1
Ending balance (in shares) at Jun. 30, 2023			(5,600,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(263.4)					(263.4)
Share-based compensation activity	3.9			3.9
Other comprehensive income (loss), net of tax	$ (1)				(1)
Ending balance (in shares) at Sep. 30, 2023	57,400,000	57,400,000
Ending balance at Sep. 30, 2023	$ 697.2	$ 0.1	$ (227.7)	$ 899.7	$ (2.6)	$ 27.7
Ending balance (in shares) at Sep. 30, 2023	(5,600,000)		(5,600,000)

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Changes in Stockholders' Equity (Parenthetical) - $ / shares	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021
Statement of Stockholders' Equity [Abstract]
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001	$ 0.001	$ 0.001	$ 0.001	$ 0.001	$ 0.001	$ 0.001

Nature of the business and orga

Nature of the business and organization	9 Months Ended
	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of the business and organization	Nature of the business and organization Organization and business Emergent BioSolutions Inc., including its consolidated subsidiaries (“Emergent,” the “Company,” “we,” “us,” and “our”) is a global life sciences company focused on providing innovative preparedness and response solutions addressing accidental, deliberate, and naturally occurring Public Health Threats ("PHTs"). The Company's solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing ("CDMO") services portfolio. The Company is focused on the following four PHT categories: chemical, biological, radiological, nuclear and explosives; emerging infectious diseases; emerging health crises; and acute/emergency care. The Company has a current product portfolio of 12 products (vaccines, therapeutics, and drug-device combination products). The revenue generated by the products comprises a substantial portion of the Company's revenue. The Company structures the business with a focus on markets and customers. As such, the key components of the business structure include the following four product and service categories: Anthrax - Medical Countermeasures ("MCM") Products, NARCAN ® , Smallpox - MCM Products and CDMO Services. The Company operates as two operating segments: (1) a products segment ("Products") consisting of the Anthrax - MCM products, NARCAN ® , Smallpox - MCM products and Other products and (2) a services segment ("Services") focused on CDMO services. Refer to Note 17, "Segment information " for additional information . The Company's products and services include: Anthrax - MCM Products • Anthrasil ® (Anthrax Immune Globulin Intravenous (human)), the only polyclonal antibody therapeutic licensed by the United States Food and Drug Administration (“FDA”) and Health Canada for the treatment of inhalational anthrax in combination with appropriate antibacterial drugs; • BioThrax ® (Anthrax Vaccine Adsorbed), the only vaccine licensed by the FDA for the general use prophylaxis and post-exposure prophylaxis of anthrax disease; • CYFENDUS™ (Anthrax vaccine adsorbed (AVA), adjuvanted), previously known as AV7909, which was recently approved by the FDA for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis in persons 18 through 65 years of age when administered in conjunction with recommended antibacterial drugs. CYFENDUS™ is procured by certain authorized government buyers for their use; and • Raxibacumab injection, the first fully human monoclonal antibody therapeutic licensed by the FDA for the treatment and prophylaxis of inhalational anthrax; NARCAN ® • NARCAN ® (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone approved by the FDA (including in over-the-counter form) and Health Canada for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression; Smallpox - MCM Products • ACAM2000 ® , (Smallpox (Vaccinia) Vaccine, Live), the only single-dose smallpox vaccine licensed by the FDA for active immunization against smallpox disease for persons determined to be at high risk for smallpox infection; • CNJ-016 ® (Vaccinia Immune Globulin Intravenous (Human) (VIGIV)), the only polyclonal antibody therapeutic licensed by the FDA and Health Canada to address certain complications from smallpox vaccination; and • TEMBEXA ® , an oral antiviral formulated as 100 mg tablets and 10 mg/mL oral suspension dosed once weekly for two weeks which has been approved by the FDA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients, including neonates. Other Products • BAT ® (Botulism Antitoxin Heptavalent (A,B,C,D,E,F,G)-(Equine)), the only heptavalent antitoxin licensed by the FDA and Health Canada for the treatment of symptomatic botulism; • Ebanga™ (ansuvimab-zykl), a monoclonal antibody with antiviral activity provided through a single IV infusion for the treatment of Ebola. Under the terms of a collaboration with Ridgeback Biotherapeutics ("Ridgeback"), Emergent will be responsible for the manufacturing, sale, and distribution of Ebanga™ in the U.S. and Canada, and Ridgeback will serve as the global access partner for Ebanga™; • RSDL ® (Reactive Skin Decontamination Lotion Kit), the only medical device cleared by the FDA that is intended to remove or neutralize chemical warfare agents from the skin, including: tabun, sarin, soman, cyclohexyl sarin, VR, VX, mustard gas and T-2 toxin; and • Trobigard® atropine sulfate, obidoxime chloride auto-injector, a combination drug-device auto-injector procured product candidate that contains atropine sulfate and obidoxime chloride. Trobigard ® was approved in Belgium in 2021 but has not been approved by the FDA. Trobigard ® is procured by certain authorized government buyers under special circumstances for potential use as a nerve agent countermeasure outside of the U.S. Sale of Travel Health Business On May 15, 2023, the Company completed the sale of its products segment's travel health business, including rights to Vivotif®, the licensed typhoid vaccine; Vaxchora®, the licensed cholera vaccine; the development-stage chikungunya vaccine candidate CHIKV VLP; the Company’s manufacturing site in Bern, Switzerland; and certain of its development facilities in San Diego, California. For additional information, refer to Note 3, "Divestiture". Services - Contract Development and Manufacturing The Company's services line focused on CDMO offerings cover development services, drug substance manufacturing, drug product manufacturing, and when necessary, suite reservations, which depending on facts and circumstances could be considered a lease. These services are provided to customers from across the pharmaceutical and biotechnology industries as well as the U.S. Government (“USG”) and non-governmental organizations. The Company's technology platforms include mammalian, microbial, viral, plasma and advanced therapies utilizing the Company's core capabilities for manufacturing to third parties on a clinical and commercial (small and large) scale. Additional services include fill/finish formulation and analytical development services for injectable and other sterile products, inclusive of process design, technical transfer, manufacturing validations, aseptic filling, lyophilization, final packaging and stability studies, as well as manufacturing of vial and pre-filled syringe formats on multiple platforms. In August 2023, the Company initiated an organizational restructuring plan (the “August 2023 Plan”) which included actions to reduce investment in and de-emphasize focus on its CDMO services business.

Summary of significant accounti

Summary of significant accounting policies	9 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
Summary of significant accounting policies	Summary of significant accounting policies Basis of presentation and consolidation The accompanying unaudited condensed consolidated financial statements include the accounts of Emergent and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements included herein have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X issued by the Securities and Exchange Commission ("SEC"). Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in Amendment No. 1 to the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2022, as filed with the SEC on December 11, 2023. In connection with the 2022 adjustments described in Note 18, “Adjustments to quarterly financial data”, there were immaterial adjustments, both individually and in the aggregate, that impacted the Company’s 2023 quarterly filings for the periods ended March 31, 2023 and June 30, 2023. All other adjustments contained in the accompanying unaudited condensed consolidated financial statements are of a normal recurring nature and are necessary to present fairly the financial position of the Company as of September 30, 2023. Interim results are not necessarily indicative of results that may be expected for any other interim period or for an entire year. Going concern As of September 30, 2023, there is $211.2 million outstanding on the Company's Revolving Credit Facility and $202.1 million on Term Loan Facility that matures in May 2025. The Company determined that there is substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the financial statements are issued. This evaluation considered the mitigating effect of management’s plans that have been implemented as of September 30, 2023. Management may evaluate the mitigating effect of its plans to determine if it is probable that (1) the plans will be effectively implemented within one year after the date the financial statements are issued, and (2) when implemented, the plans will mitigate the relevant conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern. The Company's plans include (A) amending the agreement for the Senior Secured Credit Facilities, which occurred on May 15, 2023, with the Fourth Amendment to Amended and Restated Credit Agreement, Waiver and First Amendment to Amended and Restated Collateral Agreement (the “Credit Agreement Amendment”), and (B) the execution of the capital raise requirement prescribed in the Credit Agreement Amendment, as further described below. While the Company executed the Credit Agreement Amendment and extended the maturity date on the Senior Secured Credit Facilities to May 15, 2025, the Credit Agreement Amendment also requires the Company maintain a minimum consolidated EBITDA through February 29, 2024 and to raise at least $75.0 million through the issuance of equity and/or unsecured indebtedness by April 30, 2024. As a result of these provisions, the Company has determined it is appropriate to continue to classify the debt as a current liability on the Condensed Consolidated Balance Sheets. Additional information on the nature and status of our debt covenant compliance is included below. Debt Covenants The Company has a senior secured credit facility that matures in May 2025 (the “Credit Facility”) which provides for (1) revolving credit commitments, (2) a term loan, and (3) the issuance of commercial letters of credit. As of September 30, 2023, we had $413.3 million outstanding under the Credit Facility. Under the Credit Facility, the Company is subject to a monthly minimum consolidated EBITDA covenant through February 29, 2024 and is also required to raise at least $75.0 million through the issuance of equity and/or unsecured indebtedness by April 30, 2024. As of September 30, 2023, we were in compliance with all of the covenants and restrictions associated with, and no events of default existed under, the Credit Facility. However, based on the timing of the USG procurement of the remaining 2023 order for CYFENDUS TM and a number of other product sales through the end of 2023, the Company anticipates that, absent a cure or waiver, it may be in breach of the minimum consolidated EBITDA covenant as early as the reporting date for the measurement period ending December 31, 2023. In the event the Company remains in compliance with the minimum consolidated EBITDA covenant through the measurement period ending December 31, 2023, the Company anticipates that, absent a cure or waiver of the minimum consolidated EBITDA covenant, it may be in breach of the minimum consolidated EBITDA covenant as early as the reporting date for the measurement period ending February 29, 2024. In addition, the Company is required to deliver audited annual financial statements without a “going concern” or like qualification or exception with respect to our financial statements for the year ended December 31, 2023 within 90- days of year end. The Credit Facility and the Company’s other debt facilities are described in more detail below in Note 10, “Debt” and in Note 9, “Debt” in Amendment No. 1 to the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2022. If the Company is not compliant with the covenants an event of default may occur under the Credit Facility and the agent and requisite lenders thereunder could take actions to exercise certain rights and remedies as described in the Credit Facility. Further, acceleration of the Credit Facility would result in a cross-default of the Company’s obligations under the 3.875% Senior Unsecured Notes due in 2028. If the Company would be unable to obtain a waiver or forbearance of such covenants or defaults, to successfully renegotiate the terms of the Credit Facility, or to cure the potential covenant breach or default, and the lenders enforced one or more of their rights upon default and/or the default resulted in a cross-default under certain other of the Company’s debt instruments, the Company would be unable to meet its obligations and could be forced into insolvency proceedings. Based on the facts and circumstances described above, management cannot make the assumption that it is probable that these debt covenants will be met. As a result, the Company continues to evaluate a number of uncertain factors related to its assessment of its ability to satisfy the capital raise requirement, including its ability to comply with the terms and operating and financial covenants required by the Senior Secured Credit Facilities, other market conditions, economic conditions, particularly in the pharmaceutical and biotechnology industry, and disruptions or volatility caused by factors such as regional conflicts, inflation, and supply chain disruptions. The Company has engaged legal and financial advisors to assist with a comprehensive review of alternatives to enhance its capital structure, which may include taking steps to cure any potential defaults or seeking forbearance, waivers, further cost reductions or other alternatives to avoid an event of default. The Condensed Consolidated Financial Statements have been prepared assuming the Company will continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Revenue recognition Beginning in the third quarter of 2023, the Company launched the over-the-counter NARCAN ® (naloxone HCl) Nasal Spray, 4mg (“NARCAN ® OTC”), which was approved by the FDA as an over-the-counter emergency treatment of opioid overdose, broadening our customer base and sales channels to retail pharmacies and digital commerce websites. Refer to Note 13, "Revenue recognition" for more information regarding revenue recognition accounting policies related to NARCAN ® OTC product sales. Pre-launch inventory Within the Company's Products segment, costs relating to raw materials and production of inventory in preparation for product launch prior to regulatory approval are capitalized when the review process has progressed to a point where objective and persuasive evidence exists that regulatory approval is probable, the future economic benefit is expected to be realized, and the Company believes that material uncertainties related to the ultimate regulatory approval have been significantly reduced. Pre-launch inventory is recorded to research and development expense unless these criteria are met. For pre-launch inventory that is capitalized, the Company considers a number of specific facts and circumstances, including the product candidate’s current status in the drug development and regulatory approval process, results from related clinical trials, results from meetings with relevant regulatory agencies prior to the filing of regulatory applications, potential obstacles to the approval process, historical experience, viability of commercialization and market trends. This policy is not applicable to pre-launch inventory purchased to satisfy a performance obligation related to a CDMO contract as CDMO pre-launch inventory may be capitalized if it has future economic benefit based on the terms of the contract. Significant accounting policies With the exception of the policies on revenue recognition and pre-launch inventory discussed above, there have been no significant changes to the Company's summary of significant accounting policies during the nine months ended September 30, 2023, contained in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2022, that have materially impacted the presentation of the Company's financial statements. Fair value measurements Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability, an exit price, in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value, includes: Level 1 — Observable inputs for identical assets or liabilities such as quoted prices in active markets; Level 2 — Inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3 — Unobservable inputs in which little or no market data exists, which are therefore developed by the Company using estimates and assumptions that reflect those that a market participant would use. On a recurring basis, the Company measures and records money market funds (Level 1), interest-rate swap arrangements and time deposits (Level 2) and contingent purchase consideration (Level 3) using fair value measurements in the accompanying financial statements. The carrying amounts of the Company's short-term financial instruments, which include cash and cash equivalents, accounts receivable and accounts payable approximate their fair values due to their short maturities. The carrying amounts of the Company’s long-term variable interest rate debt arrangements (Level 2) approximate their fair values. New accounting standards From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board that the Company adopts as of the pronouncement's specified effective date. There were no new accounting pronouncements that were issued or became effective since the issuance of the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 that had, or are expected to have, a material impact on its consolidated financial position, results of operations or cash flows.

Divestiture

Divestiture	9 Months Ended
	Sep. 30, 2023
Discontinued Operations and Disposal Groups [Abstract]
Divestiture	Divestiture On May 15, 2023, pursuant to the Purchase and Sale Agreement (the “Purchase and Sale Agreement”), by and between the Company, through its wholly owned subsidiaries Emergent International Inc. and Emergent Travel Health Inc., and Bavarian Nordic ("Bavarian Nordic”), the Company completed the previously announced sale of the Company’s travel health business, including rights to Vivotif®, the licensed typhoid vaccine; Vaxchora®, the licensed cholera vaccine; the development-stage chikungunya vaccine candidate CHIKV VLP; the Company’s manufacturing site in Bern, Switzerland; and certain of its development facilities in San Diego, California. At the closing, Bavarian Nordic paid a cash purchase price of $270.0 million, exclusive of customary closing adjustments for cash, indebtedness, working capital and transaction expenses of the business at closing. Bavarian Nordic may also be required to pay milestone payments of up to $80.0 million related to the development of CHIKV VLP and receipt of marketing approval and authorization in the U.S. and Europe, and earn-out payments of up to $30.0 million based on aggregate net sales of Vaxchora and Vivotif in calendar year 2026. As a result of the divestiture, during the nine months ended September 30, 2023, the Company recognized a pre-tax gain of $74.2 million, net of transaction costs of $4.0 million recorded within "Gain on sale of business" on the Condensed Consolidated Statements of Operations. During the three months ended September 30, 2023, a measurement period adjustment of $0.7 million was recognized, which reduced the gain. The reduction represents a working capital adjustment, payable to Bavarian Nordic. The Company determined that the disposal of the travel health business does not qualify for reporting as a discontinued operation since it does not represent a strategic shift that has or will have a major effect on our operations and financial results. No adjustments were made to prior period results as a result of the disposal. In connection with the divestiture, the Company entered into a Transition Services Agreement (“TSA”) with Bavarian Nordic to help support its ongoing operations. Under the TSA, the Company provides certain transition services to Bavarian Nordic, including information technology, finance and enterprise resource planning, research and development, human resources, employee benefits and other limited services. Income from performing services under the TSA was recorded within "Other, net" on the Condensed Consolidated Statements of Operations and was $1.2 million and $2.2 million for the three and nine months ended September 30, 2023, respectively.

Long-lived asset impairment and

Long-lived asset impairment and restructuring charges	9 Months Ended
	Sep. 30, 2023
Restructuring and Related Activities [Abstract]
Long-lived asset impairment and restructuring charges	Long-lived asset impairment and restructuring charges Impairment of long-lived assets The Company tests its long-lived assets that are held and used for recoverability whenever events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable. During the second quarter of 2023, due to deterioration in performance and resulting downward revisions to our internal CDMO forecast made during the second quarter, including future expected cash flows, the Company determined there were sufficient indicators of impairment on certain asset groups within the CDMO reporting unit to require an impairment analysis. As a result, the Company performed recoverability tests on certain asset groups within the CDMO reporting unit and concluded that the impacted asset groups were not recoverable as the undiscounted expected cash flows did not exceed their carrying values. Asset groups are written down only to the extent that their carrying value is higher than their respective fair value. The Company, with the assistance of a third-party valuation firm, applied valuation methods to estimate the fair values for each of the assets within the different asset classes. An orderly liquidation value was applied to estimate the fair value of the personal property assets and market and cost based approaches were applied to estimate the fair value of the real property assets. All of the valuation approaches applied represented Level 3 non-recurring fair value measurements. Based on this analysis, the Company allocated and recognized a non-cash impairment charge of $306.7 million during the nine months ended September 30, 2023. The table below presents the total impairment charge by asset class for the three and nine months ended September 30, 2023: Three Months Ended September 30, 2023 Nine Months Ended September 30, 2023 Buildings, building improvements and leasehold improvements $ — $ 81.5 Furniture and equipment — 117.5 Software — 0.3 Construction-in-progress — 107.4 Total impairment of long-lived assets $ — $ 306.7 January 2023 Organizational Restructuring Plan In January 2023, the Company initiated an organizational restructuring plan (the “January 2023 Plan”) intended to reduce operating costs, improve operating margins, and continue advancing the Company’s ongoing commitment to profitable growth. As part of the January 2023 Plan, the Company reduced its workforce by approximately 125 employees. The Company made a $(0.2) million adjustment to the incurred charges in connection with the January 2023 Plan during the three months ended September 30, 2023 and incurred approximately $9.4 million in charges during the nine months ended September 30, 2023. These charges consist primarily of charges related to employee transition, severance payments and employee benefits. All activities related to the January 2023 Plan were substantially completed during the first quarter of 2023. Restructuring costs are recognized as an operating expense within the Condensed Consolidated Statement of Operations and are classified based on the Company's classification policy for each category of operating expense. August 2023 Organizational Restructuring Plan In August 2023, the Company initiated the August 2023 Plan intended to strengthen its core business and financial position by reducing investment in and de-emphasizing focus on its CDMO services business for future growth. As part of the August 2023 Plan, the Company reduced its workforce by approximately 400 employees. The Company incurred approximately $20.5 million in charges in connection with the August 2023 Plan during the three months ended September 30, 2023. These charges consist primarily of charges related to severance payments, transition services, and employee benefits. All activities related to the August 2023 Plan were substantially completed during the third quarter of 2023. Restructuring costs are recognized as an operating expense within the Condensed Consolidated Statement of Operations and are classified based on the Company's classification policy for each category of operating expense. The following table presents the total restructuring costs associated with the Company’s segments as well as unallocated corporate and research and development ("R&D") charges for the three and nine months ended September 30, 2023: Three Months Ended Nine Months Ended Products $ 5.0 $ 7.0 Services 8.1 8.1 Total restructuring costs by segment 13.1 15.1 Corporate 6.3 11.4 R&D $ 0.9 3.4 Total restructuring costs $ 20.3 $ 29.9 The following table presents the total restructuring costs, by function, for the three and nine months ended September 30, 2023: Three Months Ended Nine Months Ended Employee transition $ 0.3 $ 0.6 Severance payments 17.9 26.6 Employee benefits 2.1 2.7 Total restructuring costs $ 20.3 $ 29.9 The following table provides the components of and changes in the Company's restructuring accrual for the January 2023 Plan during the three and nine months ended September 30, 2023: Employee Transition Severance Payments Employee Benefits Total Balance at December 31, 2022 $ — $ — $ — $ — Accruals 0.3 8.7 0.7 9.7 Cash payments (0.2) (2.0) (0.1) (2.3) Balance at March 31, 2023 $ 0.1 $ 6.7 $ 0.6 $ 7.4 Accruals — 0.1 (0.2) (0.1) Cash payments — (3.6) (0.1) (3.7) Balance at June 30, 2023 $ 0.1 $ 3.2 $ 0.3 $ 3.6 Accruals — — (0.2) (0.2) Cash payments — (1.1) — (1.1) Balance at September 30, 2023 $ 0.1 $ 2.1 $ 0.1 $ 2.3 The following table provides the components of and changes in the Company's restructuring accrual for the August 2023 Plan during the three and nine months ended September 30, 2023: Employee Transition Severance Payments Employee Benefits Total Balance at December 31, 2022 $ — $ — $ — $ — Accruals — — — — Cash payments — — — — Balance at March 31, 2023 $ — $ — $ — $ — Accruals — — — — Cash payments — — — — Balance at June 30, 2023 $ — $ — $ — $ — Accruals 0.3 17.9 2.3 20.5 Cash payments (0.2) (1.7) — (1.9) Balance at September 30, 2023 $ 0.1 $ 16.2 $ 2.3 $ 18.6

Inventories, net

Inventories, net	9 Months Ended
	Sep. 30, 2023
Inventory Disclosure [Abstract]
Inventories, net	Inventories, net Inventories, net consisted of the following: September 30, 2023 December 31, 2022 (As Restated) Raw materials and supplies $ 142.3 $ 142.3 Work-in-process 146.3 116.2 Finished goods 65.5 92.2 Total inventories, net $ 354.1 $ 350.7 Inventories, net is stated at the lower of cost or net realizable value .

Property, plant and equipment,

Property, plant and equipment, net	9 Months Ended
	Sep. 30, 2023
Property Plant and Equipment Income Statement Disclosures [Abstract]
Property, plant and equipment, net	Property, plant and equipment, net Property, plant and equipment, net consisted of the following: September 30, 2023 (1) December 31, 2022 Land and improvements $ 30.0 $ 54.9 Buildings, building improvements and leasehold improvements 228.9 327.9 Furniture and equipment 428.5 567.5 Software 64.0 65.6 Construction-in-progress 44.9 185.5 Property, plant and equipment, gross $ 796.3 $ 1,201.4 Less: Accumulated depreciation & amortization (400.9) (383.8) Total property, plant and equipment, net $ 395.4 $ 817.6 (1) During the nine months ended September 30, 2023, the Company recorded a non-cash impairment charge of $306.7 million related to certain CDMO long-lived assets. See Note 4, "Long-lived asset impairment and restructuring charges" for more details regarding the impairment charge. As of September 30, 2023, construction-in-progress primarily included costs incurred to advance the Company's MCM Product capabilities. As of December 31, 2022, construction-in-progress primarily included costs incurred due to construction to advance the Company's CDMO capabilities. Property, plant and equipment, net is stated at cost, less accumulated depreciation and amortization. During the year ended December 31, 2022, the Company recorded accelerated depreciation of $12.7 million reflecting a shortening of the useful life of certain property, plant and equipment which were to be used in the manufacturing process to fulfill the manufacturing services agreement (the "Janssen Agreement") with Janssen Pharmaceuticals, Inc. ("Janssen"). For additional information related to the termination of the Janssen Agreement, refer to Note 13, "Revenue recognition".

Intangible assets and goodwill

Intangible assets and goodwill	9 Months Ended
	Sep. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible assets and goodwill	Intangible assets and goodwill The Company's finite-lived intangible assets consist of products acquired via business combinations or asset acquisitions. The following table summarizes the Company's finite-lived intangible assets: Weighted Average Useful Life in Years September 30, 2023 December 31, 2022 Gross Carrying Amount Accumulated Amortization Net Carrying Amount (1) Gross Carrying Amount Accumulated Amortization Net Carrying Amount Products (2) 13.5 $ 855.4 $ 272.6 $ 582.8 $ 982.1 $ 253.3 $ 728.8 Customer relationships 0.0 28.6 28.6 — 28.6 28.6 — CDMO 0.0 5.5 5.5 — 5.5 5.5 — Total intangible assets $ 889.5 $ 306.7 $ 582.8 $ 1,016.2 $ 287.4 $ 728.8 (1) During the nine months ended September 30, 2023, the Company sold $102.9 million of intangible assets, net as part of the sale of its travel health business to Bavarian Nordic. See Note 3, "Divestiture" for more information on the sale of the travel health business. (2) During the three months ended September 30, 2023, the Company recorded a $6.3 million intangible asset addition related to the contingent consideration payment to Ridgeback for the award of a 10-year contract by the Biomedical Advanced Research and Development Authority for advanced development, manufacturing scale-up, and procurement of Ebanga TM treatment for Ebola. The related intangible asset was acquired through an asset acquisition that was completed in 2022. Amortization expense associated with the Company's intangible assets was recorded as follows: Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Amortization expense $ 16.3 $ 14.0 $ 49.4 $ 42.0 The table below summarizes the changes in the carrying amount of goodwill by reportable segment: Products (1) Services (2) Total Balance at December 31, 2022 $ 218.2 $ — $ 218.2 Goodwill impairment (218.2) — (218.2) Balance at September 30, 2023 $ — $ — $ — (1) Amounts for the Company's Products segment include gross carrying values of $259.9 million as of September 30, 2023 and December 31, 2022 and accumulated impairment losses of $259.9 million. (2) Amounts for the Company's Services segment include gross carrying values of $6.7 million as of September 30, 2023 and December 31, 2022, and accumulated impairment losses of $6.7 million. The Company performs its goodwill impairment evaluation annually, during the fourth quarter, or sooner if triggering events are identified. During the three months ended September 30, 2023, the Company observed continued market volatility including significant declines in its market capitalization and revised its financial outlook during the third quarter of 2023, which was identified as a triggering event. As a result of the quantitative assessments performed in connection with the preparation of the financial statements as of and for the quarter ended September 30, 2023, the Company recorded a $218.2 million non-cash goodwill impairment charge for the MCM reporting unit within the Products segment, which is included in "Goodwill impairment" on the Condensed Consolidated Statement of Operations for the three and nine months ended September 30, 2023. The MCM reporting unit and Products segment had no remaining goodwill as of September 30, 2023. The goodwill impairment

Fair value measurements

Fair value measurements	9 Months Ended
	Sep. 30, 2023
Fair Value Disclosures [Abstract]
Fair value measurements	Fair value measurements The table below presents information about the Company's assets and liabilities that are regularly measured and carried at fair value and indicates the level within the fair value hierarchy of the valuation techniques the Company utilized to determine fair value: September 30, 2023 December 31, 2022 (As Restated) Total Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Assets: Money market accounts $ 37.2 $ 37.2 $ — $ — $ 320.8 $ 320.8 $ — $ — Time deposits — — — — 170.7 — 170.7 — Derivative instruments — — — — 8.5 — 8.5 — Total $ 37.2 $ 37.2 $ — $ — $ 500.0 $ 320.8 $ 179.2 $ — Liabilities: Contingent consideration $ 5.4 $ — $ — $ 5.4 $ 8.0 $ — $ — $ 8.0 Total $ 5.4 $ — $ — $ 5.4 $ 8.0 $ — $ — $ 8.0 Contingent consideration Contingent consideration payments in an asset acquisition not required to be accounted for as derivatives are recognized when the contingency is resolved, and the consideration is paid or becomes payable. Contingent consideration liabilities associated with business combinations are measured at fair value. These liabilities represent an obligation of the Company to transfer additional assets to the selling shareholders and owners if future events occur or conditions are met. These liabilities associated with business combinations are measured at fair value at inception and at each subsequent reporting date. The changes in the fair value are primarily due to the expected amount and timing of future net sales, which are inputs that have no observable market. Any changes in fair value for the contingent consideration liabilities related to the Company’s products are classified on the Company's Condensed Consolidated Statement of Operations as "Cost of product sales." The table below is a reconciliation of the beginning and ending balance of the Company's Level 3 contingent consideration liability: Contingent Consideration Balance at December 31, 2022 (As Restated) $ 8.0 Change in fair value 0.3 Settlements (0.7) Balance at March 31, 2023 $ 7.6 Change in fair value 0.4 Settlements (0.6) Balance at June 30, 2023 $ 7.4 Change in fair value (1.1) Settlements (0.9) Balance at September 30, 2023 $ 5.4 As of September 30, 2023 and December 31, 2022, the current portion of the contingent consideration liability was $2.1 million and $3.4 million, respectively, and was included in "Other current liabilities" on the Condensed Consolidated Balance Sheets. The non-current portion of the contingent consideration liability is included in "Other liabilities" on the Condensed Consolidated Balance Sheets. The recurring Level 3 fair value measurement for the Company's contingent consideration liability used the following significant unobservable inputs: Contingent Consideration Liability Fair Value as of September 30, 2023 Valuation Technique Unobservable Input Range Royalty based $5.4 million Discounted cash flow Discount rate 10.4% Probability of payment 0% - 75% Projected year of payment 2023 - 2028 Derivative instruments Refer to Note 9, "Derivative instruments and hedging activities " for more information about the Company's derivative instruments. Non-variable rate debt As of September 30, 2023 and December 31, 2022, t he fair value of the Company's 3.875% Senior Unsecured Notes due 2028 (the "2028 Notes") was $190.1 million and $225.1 million, respectively. The fair value was determined through market sources, which are Level 2 inputs and directly observable. The carrying amounts of the Company’s other long-term variable interest rate debt arrangements approximate their fair values (see Note 10, "Debt").

Derivative instruments and hedg

Derivative instruments and hedging activities	9 Months Ended
	Sep. 30, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative instruments and hedging activities	Derivative instruments and hedging activities Risk management objective of using derivatives The Company is exposed to certain risks arising from both its business operations and economic conditions. The Company principally manages its exposures to a wide variety of business and operational risks through management of its core business activities. The Company manages economic risks, including interest rate, liquidity and credit risk primarily by managing the amount, sources and duration of its assets and liabilities and the use of derivative financial instruments. From time to time, the Company enters into interest rate swap transactions to manage exposures that arise from payments of variable interest rate debt associated with the Company's senior secured credit agreements. The objective and strategy with respect to these interest rate swaps is to protect the Company against adverse fluctuations in interest rates. During the second quarter of 2023, the Company terminated its designated interest rate swap transactions with a total notional value of $350.0 million. Hedge accounting was also discontinued at that time. As of September 30, 2023, the remaining accumulated other comprehensive income associated with the terminated interest rate swaps, before tax, was $0.5 million and will be amortized to earnings over the remaining term of the interest rate swaps prior to termination. The table below presents the fair value of the Company’s derivative financial instruments designated as hedges as well as their classification on the Condensed Consolidated Balance Sheets: Fair Value of Asset Derivatives Classification September 30, 2023 December 31, 2022 Interest Rate Swaps Other Current Assets $ — $ 8.5 The valuation of the interest rate swaps is determined using widely accepted valuation techniques, including discounted cash flow analysis on the expected cash flows of each interest rate swap. This analysis reflects the contractual terms of the interest rate swaps, including the period to maturity, and uses observable market-based inputs, including interest rate curves and implied volatilities. The fair values of interest rate swaps are determined using the market standard methodology of netting the discounted future fixed cash payments (or receipts) and the discounted expected variable cash receipts (or payments). The variable cash payments (or receipts) are based on an expectation of future interest rates (forward curves) derived from observable market interest rate curves. We incorporate credit valuation adjustments in the fair value measurements to appropriately reflect both our own nonperformance risk and the respective counterparty’s nonperformance risk. These credit valuation adjustments were not significant inputs for the fair value calculations for the periods presented. In adjusting the fair value of our derivative contracts for the effect of nonperformance risk, we have considered the impact of netting and any applicable credit enhancements, such as the posting of collateral, thresholds, mutual puts and guarantees. The valuation of interest rate swaps fall into Level 2 in the fair value hierarchy. The following table summarizes the amount of gains or losses reclassified from "Accumulated other comprehensive income (loss), net" into "Interest expense" on the Condensed Consolidated Statement of Operations during the three and nine months ended September 30, 2023 and 2022: Classification Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Interest rate swaps gain (loss) Interest expense $ 3.1 $ 0.4 $ 8.4 $ (1.9)

Debt

Debt	9 Months Ended
	Sep. 30, 2023
Debt Disclosure [Abstract]
Debt	Debt The table below presents the components of the Company’s debt: September 30, 2023 December 31, 2022 Senior secured credit agreement - Term loan due 2025 $ 202.1 $ 362.8 Senior secured credit agreement - Revolver loan due 2025 211.2 598.0 3.875% Senior Unsecured Notes due 2028 450.0 450.0 Other 3.0 3.0 Total debt $ 866.3 $ 1,413.8 Less: Unamortized debt issuance costs (1) (4.5) (8.0) Less: Current portion of long-term debt, net (413.6) (957.3) Non-current portion of debt, net $ 448.2 $ 448.5 (1) As of September 30, 2023, excludes the unamortized debt issuance costs related to the revolver loan which are included within "Other current assets" on the accompanying Condensed Consolidated Balance Sheet. During the second quarter of 2023, the Company reclassified the debt issuance costs associated with the revolver loan to "Other current assets." Prior to the second quarter of 2023, the debt issuance costs associated with the revolver loan were classified as a direct offset to the carrying value of the debt within "Other current liabilities." As of September 30, 2023 and December 31, 2022, the Company had $9.4 million and $1.3 million of debt issuance costs associated with the revolver loan, respectively. 3.875% Senior Unsecured Notes due 2028 On August 7, 2020, the Company completed its offering of $450.0 million aggregate principal amount of 3.875% 2028 Notes . Interest on the 2028 Notes is payable on February 15th and August 15th of each year until maturity, beginning on February 15, 2021. The 2028 Notes will mature on August 15, 2028. As of August 15, 2023, the Company may redeem the 2028 Notes, in whole or in part, at the redemption prices set forth in the related indenture, plus accrued and unpaid interest. As of August 15, 2023, the Company may redeem all or a portion of the 2028 Notes at a redemption price equal to 100% of the principal amount of the 2028 Notes plus a “make-whole” premium and accrued and unpaid interest as set forth in the related indenture. Upon the occurrence of a change of control, the Company must offer to repurchase the 2028 Notes at a purchase price of 101% of the principal amount of such 2028 Notes plus accrued and unpaid interest. Negative covenants in the indenture governing the 2028 Notes, among other things, limit the ability of the Company to incur indebtedness and liens, dispose of assets, make investments, enter into certain merger or consolidation transactions and make restricted payments. Senior Secured Credit Facilities On May 15, 2023, the Company entered into the Credit Agreement Amendment. The Credit Agreement Amendment amended the Existing Credit Agreement to, among other things, (a) extend the maturity date of the Senior Secured Credit Facilities from October 13, 2023 to May 15, 2025, (b) reduce the available commitments under the Revolving Credit Facility from $600.0 million to $300.0 million, (c) remove the Company's ability to incur incremental loans and (d) amend certain mandatory prepayment triggers, affirmative covenants, negative covenants and events of default thereunder. In connection with the Credit Agreement Amendment, the Company used the approximately $270.0 million of proceeds from the sale of its travel health business to Bavarian Nordic, which closed on May 15, 2023, together with approximately $217.2 million of cash on hand, to repay approximately $144.4 million in outstanding principal amount of loans under the Term Loan Facility and $342.8 million outstanding principal amount of loans under the Revolving Credit Facility. The Credit Agreement Amendment also requires that the Company make quarterly principal payments on the Term Loan Facility of approximately $3.9 million, which commenced on June 30, 2023 and will extend through March 31, 2025. The Credit Agreement Amendment also (w) amended the consolidated debt service coverage ratio financial covenant to require the minimum level to be 2.25 to 1.00 for the fiscal quarters ending March 31, 2024, June 30, 2024, September 30, 2024 and December 31, 2024, and then 2.50 to 1.00 for each fiscal quarter ending thereafter, (x) amended the consolidated leverage ratio to require the maximum level to be 4.50 to 1.00 for the fiscal quarter ending March 31, 2024 and each fiscal quarter ending thereafter, (y) added minimum Consolidated EBITDA requirements and maximum capital expenditure requirements for each of the months ending April 30, 2023 through February 29, 2024 and a minimum liquidity requirement as of the end of each calendar month and (z) requires the Company to increase its liquidity by April 30, 2024 by raising at least $75.0 million of equity or unsecured indebtedness. In addition, the Credit Agreement Amendment replaced the interest rate benchmark such that borrowings under the Revolving Credit Facility and the outstanding principal amount of the Term Loan Facility shall bear interest at a rate per annum equal to (a) a rate based on SOFR, EURIBOR or CDOR plus a margin of 6.00% until March 31, 2024 and thereafter, a margin ranging from 2.75% to 4.00% depending on the Company’s consolidated leverage ratio, or (b) a base rate (which is the highest of the prime rate, the federal funds rate plus 0.50%, and a SOFR rate for an interest period of one month plus 1%) plus a margin of 5.00% until March 31, 2024 and thereafter, a margin ranging from 1.75% to 3.00% depending on the Company’s consolidated leverage ratio. In addition, the commitment fee the Company is required to pay in respect of the annual daily unused commitments under the Revolving Credit Facility shall be 0.15% to 0.40% per annum, depending on the Company’s consolidated leverage ratio. Under the Credit Agreement Amendment, the Company and the other guarantors also agreed to provide a lien over certain assets as additional collateral for the benefit of the lenders, including owned real property, equity interests of foreign subsidiaries and certain deposit accounts.

Stock-based compensation and st

Stock-based compensation and stockholders' equity	9 Months Ended
	Sep. 30, 2023
Stockholders' Equity Note [Abstract]
Stock-based compensation and stockholders' equity	Stock-based compensation and stockholders' equity Stock-based compensation During the nine months ended September 30, 2023, the Company granted stock options to purchase 0.8 million shares of common stock, 1.6 million restricted stock units and 0.5 million performance stock units under the Emergent BioSolutions Inc. Amended and Restated Stock Incentive Plan. Performance stock units are presented at the target payout percentage of 100% of target shares granted and the maximum potential payout percentage is up to 200% of target shares granted. Typically, the stock options and restricted stock unit grants vest over three equal annual installments beginning on the day prior to the anniversary of the grant date. The performance stock units settle in stock at the end of the three-year performance period based on the Company's results compared to the performance criteria. During the nine months ended September 30, 2023, 0.9 million of stock options and 0.7 million shares of restricted stock units were forfeited prior to the completion of the applicable vesting requirements or expiration. Additionally, 0.3 million performance stock units were forfeited during the nine months ended September 30, 2023, as the award targets or vesting requirements were not achieved. Stock-based compensation expense, net of forfeitures was recorded in the following financial statement line items: Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Cost of product sales $ 1.0 $ 1.8 $ 3.6 $ 5.4 Cost of CDMO 0.2 0.4 0.8 1.4 R&D 0.6 1.3 1.7 3.9 Selling, general and administrative 2.2 7.7 13.0 22.7 Total stock-based compensation expense $ 4.0 $ 11.2 $ 19.1 $ 33.4 At-the-Market Equity Offering Facility We may, from time to time, sell up to $150.0 million aggregate gross sales price of shares of our common stock through Evercore Group L.L.C. and RBC Capital Markets, LLC, as sales agents, under an “at-the-market” equity offering program (the “ATM Program”) that we entered into on May 18, 2023. There were no sales of our common stock under the ATM Program during the three months ended September 30, 2023. Between the entry into the ATM Program and September 30, 2023, we sold 1.1 million shares of our common stock under the ATM Program for gross proceeds of $9.1 million, representing an average share price of $8.22 per share. As of September 30, 2023, $140.9 million aggregate gross sales price of shares of our common stock remains available for issuance under the ATM Program. We intend to use proceeds obtained from the sale of shares under the ATM Program for general corporate purposes. 2023 Inducement Plan On September 28, 2023, the Company's Board of Directors adopted and approved the Emergent BioSolutions, Inc. Inducement Plan (the "Inducement Plan"), pursuant to which the Company may from time to time make equity grants to individuals not previously an employee or director of the Company or any of its subsidiaries (or following a bona fide period of interruption of employment) as a material inducement to their employment by the Company. The Inducement Plan was adopted by the board of directors without stockholder approval pursuant to New York Stock Exchange Listing Rule 303A.08. The board of directors reserved 5,000,000 shares of the Company's common stock for issuance under the Inducement Plan. The terms and conditions of the Inducement Plan are substantially similar to the Company's stockholder-approved Emergent BioSolutions Inc. Amended and Restated Stock Incentive Plan. As of September 30, 2023, no shares had been issued under the Inducement Plan. 2021 Share Repurchase Program On November 11, 2021, the Company announced that its board of directors authorized a stock repurchase program of up to an aggregate of $250.0 million of common stock (the "2021 Share Repurchase Program"), of which $187.9 million was utilized to purchase approximately 4.4 million shares. The 2021 Share Repurchase Program expired on November 11, 2022. During the three months ended September 30, 2022, there were no shares repurchased. During the nine months ended September 30, 2022, the Company utilized $75.5 million to purchase approximately 1.8 million shares. The 2021 Share Repurchase Program did not obligate the Company to acquire any specific number of shares. Repurchased shares are available for use in connection with the Company's stock plans and for other corporate purposes. Accumulated other comprehensive income (loss), net of tax The following table includes changes in accumulated other comprehensive income (loss), net of tax by component: Defined Benefit Pension Plan Derivative Instruments Foreign Currency Total Balance at December 31, 2022 $ 3.5 $ 6.2 $ (6.6) $ 3.1 Other comprehensive income (loss) before reclassifications — (4.4) (0.1) (4.5) Amounts reclassified from accumulated other comprehensive income (loss) — 2.4 — 2.4 Net current period other comprehensive income (loss) — (2.0) (0.1) (2.1) Balance at March 31, 2023 $ 3.5 $ 4.2 $ (6.7) $ 1.0 Other comprehensive income (loss) before reclassifications — 1.2 2.6 3.8 Amounts reclassified from accumulated other comprehensive income (loss) (3.5) (2.9) — (6.4) Net current period other comprehensive income (loss) (3.5) (1.7) 2.6 (2.6) Balance at June 30, 2023 $ — $ 2.5 $ (4.1) $ (1.6) Other comprehensive income (loss) before reclassifications — 0.9 1.2 2.1 Amounts reclassified from accumulated other comprehensive income (loss) — (3.1) — (3.1) Net current period other comprehensive income (loss) — (2.2) 1.2 (1.0) Balance at September 30, 2023 $ — $ 0.3 $ (2.9) $ (2.6) Balance at December 31, 2021 $ (4.0) $ (4.5) $ (7.6) $ (16.1) Other comprehensive income (loss) before reclassifications — 4.9 0.5 5.4 Amounts reclassified from accumulated other comprehensive income (loss) — 1.4 — 1.4 Net current period other comprehensive income (loss) — 6.3 0.5 6.8 Balance at March 31, 2022 $ (4.0) $ 1.8 $ (7.1) $ (9.3) Other comprehensive income (loss) before reclassifications — 1.9 0.4 2.3 Amounts reclassified from accumulated other comprehensive income (loss) — 0.9 — 0.9 Net current period other comprehensive income (loss) — 2.8 0.4 3.2 Balance at June 30, 2022 $ (4.0) $ 4.6 $ (6.7) $ (6.1) Other comprehensive income (loss) before reclassifications — 2.6 (1.3) 1.3 Amounts reclassified from accumulated other comprehensive income (loss) — (0.4) — (0.4) Net current period other comprehensive income (loss) — 2.2 (1.3) 0.9 Balance at September 30, 2022 $ (4.0) $ 6.8 $ (8.0) $ (5.2) The tables below present the tax effects related to each component of other comprehensive income (loss): Three Months Ended September 30, 2023 2022 Pretax Tax Expense Net of tax Pretax Tax Expense Net of tax Defined benefit pension plan $ — $ — $ — $ — $ — $ — Derivative instruments (3.1) 0.9 (2.2) 3.0 (0.8) 2.2 Foreign currency translation adjustments 0.9 0.3 1.2 0.1 (1.4) (1.3) Total adjustments $ (2.2) $ 1.2 $ (1.0) $ 3.1 $ (2.2) $ 0.9 Nine Months Ended September 30, 2023 2022 Pretax Tax Expense Net of tax Pretax Tax Expense Net of tax Defined benefit pension plan $ (4.1) $ 0.6 $ (3.5) $ — $ — $ — Derivative instruments (8.0) 2.1 (5.9) 15.4 (4.1) 11.3 Foreign currency translation adjustments 2.9 0.8 3.7 2.1 (2.5) (0.4) Total adjustments $ (9.2) $ 3.5 $ (5.7) $ 17.5 $ (6.6) $ 10.9

Loss per common share

Loss per common share	9 Months Ended
	Sep. 30, 2023
Earnings Per Share [Abstract]
Loss per common share	Loss per common share Basic loss per common share is calculated using the treasury method by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted loss per common share adjusts basic loss per common share for the effects of potentially dilutive common shares and is calculated using the treasury stock method. Potentially dilutive common shares include the dilutive effect of shares issuable under our equity compensation plans, including stock options, restricted stock units and performance stock units. Diluted loss per share excludes anti-dilutive securities, which represent the number of potential common shares related to shares issuable under our equity compensation plan that were excluded from diluted loss per common share because their effect would have been antidilutive. The following table presents the calculation of basic and diluted loss per common share: Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 (As Restated) (As Restated) Numerator: Net loss $ (263.4) $ (87.1) $ (711.0) $ (144.6) Denominator: Weighted-average number of shares outstanding-basic 51.8 49.9 50.9 50.2 Weighted-average number of shares outstanding-diluted 51.8 49.9 50.9 50.2 Loss per common share - basic $ (5.08) $ (1.75) $ (13.97) $ (2.88) Loss per common share - diluted $ (5.08) $ (1.75) $ (13.97) $ (2.88) Anti-dilutive securities 4.0 3.3 3.6 2.6

Revenue recognition

Revenue recognition	9 Months Ended
	Sep. 30, 2023
Revenue from Contract with Customer [Abstract]
Revenue recognition	Revenue recognition We generate the majority of our revenues through product sales to our customers. We also generate revenues through CDMO services and suite reservations for and to third parties and contracts and grants revenue. The Company recognizes revenue when the Company's customers obtain control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services by analyzing the following five steps: (1) identify the contract with a customer(s); (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) the entity satisfies a performance obligation. Beginning in the third quarter of 2023, the Company launched NARCAN ® OTC, which was approved by the FDA as an over-the-counter emergency treatment of opioid overdose, broadening our customer base and sales channels to retail pharmacies and digital commerce websites. The Company's Nasal Naloxone Products are now sold commercially over-the-counter at retail pharmacies and digital commerce websites as well as through physician-directed or standing order prescriptions at retail pharmacies, health departments, local law enforcement agencies, community-based organizations, substance abuse centers and other federal agencies. The Company's NARCAN ® OTC customer contracts are fixed price contracts. The Company invoices and records revenue when the pharmacies and wholesalers receive product from the third-party logistics warehouse used by the Company, which is the point at which control is transferred to the customer. Revenues for NARCAN ® OTC are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established. Estimates of variable consideration includes allowance for returns, specialty distributor fees, wholesaler fees and prompt payment discounts. Revenues from NARCAN ® OTC are recognized to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with such variable consideration is subsequently resolved. The Company considers several factors in the estimation process for the allowance for returns of NARCAN ® OTC, including inventory levels within the distribution channel, product shelf life and historical return activity, including activity for product sold for which the return period has passed, as well as other relevant factors. Because returned product cannot be resold, there is no corresponding asset for product returns. The Company's revenues disaggregated by operating segment and major sources for the three and nine months ended September 30, 2023 and 2022 were as follows: Three Months Ended September 30, 2023 Three Months Ended September 30, 2022 USG Non-USG Total USG Non-USG Total Product sales, net $ 103.0 $ 146.8 $ 249.8 $ 33.4 $ 152.8 $ 186.2 CDMO: Services — 13.2 13.2 — 36.1 36.1 Leases — 1.0 1.0 — 0.2 0.2 Total CDMO $ — $ 14.2 $ 14.2 $ — $ 36.3 $ 36.3 Contracts and grants 5.1 1.4 6.5 16.4 1.0 17.4 Total revenues $ 108.1 $ 162.4 $ 270.5 $ 49.8 $ 190.1 $ 239.9 Nine Months Ended September 30, 2023 Nine Months Ended September 30, 2022 USG Non-USG Total USG Non-USG Total Product sales, net $ 279.6 $ 415.8 $ 695.4 $ 255.0 $ 405.5 $ 660.5 CDMO: Services — 52.2 52.2 — 87.8 87.8 Leases — 5.5 5.5 — 4.7 4.7 Total CDMO $ — $ 57.7 $ 57.7 $ — $ 92.5 $ 92.5 Contracts and grants 14.6 5.0 19.6 31.7 2.6 34.3 Total revenues $ 294.2 $ 478.5 $ 772.7 $ 286.7 $ 500.6 $ 787.3 CDMO operating leases Certain multi-year CDMO service arrangements with commercial customers include operating leases whereby the customer has the right to direct the use of and obtain substantially all of the economic benefits of specific manufacturing suites operated by the Company. The associated revenue is recognized on a straight-line basis over the term of the lease. The weighted average remaining term on the Company's operating lease components approximates 5.3 years. The Company utilizes a cost-plus model to determine the stand-alone selling price of the lease component to allocate contract consideration between the lease and non-lease components. The Company estimates future operating lease revenues to be $0.2 million in the remainder of 2023, $0.9 million in 2024, $0.9 million in 2025, $0.9 million in 2026, $0.9 million in 2027 and $0.9 million in years beyon d 2027. Transaction price allocated to remaining performance obligations As of September 30, 2023, the Company has future contract value on unsatisfied performance obligations of approximately $408.6 million associated with all arrangements entered into by the Company. The Company expects to recognize $400.3 million of unsatisfied performance obligations within the next 24 months. The amount and timing of revenue recognition for unsatisfied performance obligations can change. The future revenues associated with unsatisfied performance obligations exclude the value of unexercised option periods in the Company’s revenue arrangements. Often the timing of manufacturing activities changes based on customer needs and resource availability. Government funding appropriations can impact the timing of product deliveries. The success of the Company's development activities that receive development funding support from the USG under development contracts can also impact the timing of revenue recognition. Contract assets The Company considers accounts receivable and deferred costs associated with revenue generating contracts, which are not included in inventory or property, plant and equipment and that the Company does not currently have a contractual right to bill, to be contract assets. As of September 30, 2023 and December 31, 2022, the Company had $38.4 million an d $34.8 million , respectively, of contract assets recorded within "Accounts receivable, net" on the Condensed Consolidated Balance Sheets. Contract liabilities When performance obligations are not transferred to a customer at the end of a reporting period, cash received associated with amounts allocated to those performance obligations is reflected as contract liabilities on the Condensed Consolidated Balance Sheets and is deferred until control of these performance obligations is transferred to the customer. The following table presents the roll forward of the contract liability balances: Contract Liabilities Balance at December 31, 2022 $ 31.7 Balance at September 30, 2023 $ 27.9 Revenue recognized in the period from amounts included in contract liability at the beginning of the period: $ (7.3) As of September 30, 2023 and December 31, 2022, the current portion of contract liabilities was $22.9 million and $26.4 million, respectively, and was included in "Other current liabilities" on the Condensed Consolidated Balance Sheets. Accounts receivable and allowance for expected credit losses Accounts receivable, including unbilled accounts receivable contract assets, consist of the following: September 30, 2023 December 31, 2022 (As Restated) Accounts receivable: Billed $ 156.6 $ 102.7 Unbilled 61.0 57.2 Allowance for expected credit losses (1.1) (0.7) Accounts receivable, net $ 216.5 $ 159.2 We maintain an allowance for expected credit losses, which represents the estimated aggregate amount of credit risk arising from the inability or unwillingness of specific customers to pay our fees or disputes that may affect our ability to fully collect our billed accounts receivable. We estimate the current-period provision for expected credit losses on a specific identification basis and we consider factors such as the age of the receivables balance, knowledge of the specific customers' circumstances and historical collection experience for similar customers. Accounts receivable, net of the allowance for expected credit losses, represents the amount we expect to collect. Our actual experience may vary from our estimates. At each reporting date, we adjust the allowance for expected credit losses to reflect our current estimate. 2022 Termination of manufacturing services agreement with Janssen Pharmaceuticals, Inc. On July 2, 2020, the Company, through its wholly owned subsidiary, Emergent Manufacturing Operations Baltimore, LLC, entered into the Janssen Agreement with Janssen, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for large-scale drug substance manufacturing of Johnson & Johnson’s investigational SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant based on the AdVac technology (the “Product”). On June 6, 2022, the Company provided to Janssen a notice (the “Notice”) of material breach of the Janssen Agreement for, among other things, failure by Janssen (i) to provide the Company the requisite forecasts of the required quantity of Product to be purchased by Janssen under the Janssen Agreement and (ii) to confirm Janssen’s intent to not purchase the requisite minimum quantity of the Product pursuant to the Janssen Agreement and instead, wind-down the Janssen Agreement ahead of fulfilling these minimum requirements. Later on June 6, 2022, the Company received from Janssen a purported written notice of termination (the “Janssen Notice”) of the Janssen Agreement for asserted material breaches of the Janssen Agreement by the Company, including alleged failure by the Company to perform its obligations in compliance with current good manufacturing practices ("cGMP") or other applicable laws and regulations and alleged failure by the Company to supply Janssen with the Product. Janssen alleged that the Company’s breaches were not curable and that, therefore, termination of the Janssen Agreement would be effective as of July 6, 2022. The Company disputes Janssen's assertions and allegations, including Janssen's ability to effect termination pursuant to the Janssen Notice. The Company and Janssen disagree on the monetary amounts that are due to the Company as a result of termination by any means. The Company believes the amounts due to the Company include, but are not limited to, compensation for services provided, reimbursement for raw materials purchased and non-cancelable orders, and fees for early termination. Janssen has alleged that no additional amount is due to the Company and that the Company should pay Janssen an unspecified amount as a result of the Company's alleged failure to perform under the Janssen Agreement. The Company has not recorded any contingent liabilities related to Janssen's allegations as the Company believes they are without merit and intends to vigorously defend the Company's position during the dispute resolution process through arbitration. During the three months ended September 30, 2023, there were no impacts on previously recognized revenue or depreciation related to the conclusion of the Janssen Agreement. As of September 30, 2023, the Company has no billed or unbilled net accounts receivable related to the Janssen Agreement. Beginning in the fourth quarter of 2022, because the arbitration process is expected to extend longer than one year, the Company reclassified amounts related to the Janssen Agreement from "Inventories, net" and from "Prepaid expenses and other current assets" to "Other assets", resulting in $152.7 million in long-term assets related to the Janssen Agreement on the Condensed Consolidated Balance Sheet as of December 31, 2022. The long-term asset balance within "Other Assets" related to the Janssen Agreement as of September 30, 2023 was $153.8 million. These assets include termination penalties, certain inventory related items and raw materials inventory representing materials purchased for the Janssen Agreement which Janssen has not reimbursed. The Company evaluated the net realizable value of the inventory as of September 30, 2023, concluding that because the Janssen Agreement specifies the Company is entitled to, among other things, reimbursement of raw materials and non-cancelable orders in the event of a contract termination for any reason, the Company is entitled to payment from Janssen for these raw materials. Additionally, the Company has $5.0 million of non-cancelable orders as of September 30, 2023 which have not been received and Janssen has not reimbursed.

Leases

Leases	9 Months Ended
	Sep. 30, 2023
Leases [Abstract]
Leases	Leases The Company is the lessee for operating leases for offices, R&D facilities and manufacturing facilities. The Company determines if an arrangement is a lease at inception. Operating leases are included in right-of-use assets and liabilities. For a discussion of lessor activities, see Note 13, "Revenue recognition." The components of lease expense were as follows: Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Operating lease cost: Amortization of right-of-use assets $ 1.1 $ 1.4 $ 3.1 $ 4.2 Interest on lease liabilities 0.2 0.3 0.6 0.8 Total operating lease cost $ 1.3 $ 1.7 $ 3.7 $ 5.0 Operating lease costs are reflected as components of cost of product sales, cost of contract development and manufacturing, R&D expense and selling, general and administrative expense. Supplemental balance sheet information related to lessee activities is as follows: Leases Classification September 30, 2023 December 31, 2022 Operating lease right-of-use assets Other assets $ 17.1 $ 19.4 Operating lease liabilities, current portion Other current liabilities $ 3.5 $ 5.8 Operating lease liabilities Other liabilities 14.6 14.8 Total operating lease liabilities $ 18.1 $ 20.6 Operating leases: Weighted average remaining lease term (years) 6.3 5.9 Weighted average discount rate 5.2 % 4.1 %

Income taxes

Income taxes	9 Months Ended
	Sep. 30, 2023
Income Tax Disclosure [Abstract]
Income taxes	Income taxes The estimated effective annual tax rate as of September 30, 2023 and 2022 for the years ended December 31, 2023 and 2022, excluding the impact of discrete adjustments, was (5)% and 4%, respectively. The decrease in the estimated effective annual tax rate is primarily due to valuation allowance and goodwill impairment charges. The Company recorded a discrete tax expense (benefit) of $1.0 million and $1.0 million for the three and nine months ended September 30, 2023, respectively, and $(9.0) million and $(7.3) million for the three and nine months ended September 30, 2022, respectively. The discrete tax expense in 2023 was due to return-to-provision adjustments and share-based compensation activity which was entirely offset by a valuation allowance charge. The discrete benefit in 2022 was primarily due to return-to-provision adjustments and the benefit of the release of an indemnified uncertain tax position offset by share-based compensation activity. The Company establishes valuation allowances for deferred income tax assets in accordance with U.S. GAAP, which provides that such valuation allowances shall be established unless realization of the income tax benefits is more likely than not. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. At each reporting period, the Company considers the scheduled reversal of deferred tax liabilities and assets, available taxes in carryback periods, tax planning strategies and projected future taxable income in making this assessment. In 2022, the Company determined that it was more likely than not that certain deferred tax assets would not be realized due to reductions in estimates of future profitability and disclosure related to substantial doubt about the Company's ability to continue as a going concern. Accordingly, the Company recorded an additional valuation allowance charge of $163.1 million in calculating the estimated annual tax rate for the year ended December 31, 2023.

Litigation

Litigation	9 Months Ended
	Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Litigation	Litigation Securities and shareholder litigation With respect to the specific legal proceedings and claims described below, unless otherwise noted, the amount or range of possible losses is not reasonably estimable. There can be no assurance that the settlement, resolution, or other outcome of one or more matters, including the matters set forth below, during any subsequent reporting period will not have a material adverse effect on the Company's results of operations or cash flows for that period or on the Company's financial condition. On April 20, 2021, May 14, 2021, and June 2, 2021, putative class action lawsuits were filed against the Company and certain of its current and former senior officers in the United States District Court for the District of Maryland on behalf of purchasers of the Company’s common stock, seeking to pursue remedies under the Securities Exchange Act of 1934. These complaints were filed by Palm Tran, Inc. – Amalgamated Transit Union Local 1577 Pension Plan; Alan I. Roth; and Stephen M. Weiss, respectively. The complaints allege, among other things, that the defendants made false and misleading statements about the Company's manufacturing capabilities with respect to COVID-19 vaccine bulk drug substance (referred to herein as "CDMO Manufacturing Capabilities"). These cases were consolidated on December 23, 2021, under the caption In re Emergent BioSolutions Inc. Securities Litigation, No. 8:21-cv-00955-PWG (the "Federal Securities Class Action"). The lead plaintiffs in the consolidated matter (the "Lead Plaintiffs") are Nova Scotia Health Employees’ Pension Plan and The City of Fort Lauderdale Police & Firefighters’ Retirement System. The defendants filed a motion to dismiss on May 19, 2022 and the Lead Plaintiffs filed an opposition to that motion on July 19, 2022. A hearing on the motion to dismiss was conducted on April 19, 2023 and an order was entered on September 1, 2023, granting in part and denying in part the motion to dismiss. The defendant's answer to the complaint was filed on October 30, 2023. The defendants believe that the allegations in the complaints are without merit and intend to defend the matters vigorously. Given the uncertainty of litigation, the preliminary stage of the cases, and the legal standards that must be met for, among other things, class certification and success on the merits, the Company cannot reasonably estimate the possible loss or range of loss, if any, that may result from the consolidated action. On June 29, 2021, Lincolnshire Police Pension Fund (“Lincolnshire”), and on August 16, 2021, Pooja Sayal, filed putative shareholder derivative lawsuits in the United States District Court for the District of Maryland on behalf of the Company against certain of the Company's current and former officers and directors for breach of fiduciary duties, waste of corporate assets, and unjust enrichment, each allegation related to the CDMO Manufacturing Capabilities. In addition to monetary damages, the complaints seek the implementation of multiple corporate governance and internal policy changes. On November 16, 2021, the cases were consolidated under the caption In re Emergent BioSolutions Inc. Stockholder Derivative Litigation, Master Case No. 8:21-cv-01595-PWG. On January 3, 2022, the Lincolnshire complaint was designated as the operative complaint in the consolidated action. On April 13, 2022 the Court approved the parties' joint stipulation to and stay of the proceedings and discovery until the close of fact discovery in the Federal Securities Class Action. The defendants believe that the allegations in the complaints are without merit and intend to defend the matter vigorously. On September 15, 2021, September 16, 2021 and November 12, 2021, putative shareholder derivative lawsuits were filed by Chang Kyum Kim, Mark Nevins and Employees Retirement System of the State of Rhode Island, North Collier Fire Control and Rescue District Firefighters Pension Plan, and Pembroke Pines Firefighters & Police Officers Pension Fund, respectively, in the Court of Chancery of the State of Delaware on behalf of the Company against certain of its current and former officers and directors for breach of fiduciary duties, unjust enrichment and insider trading, each allegation related to the CDMO Manufacturing Capabilities. In addition to monetary damages, the complaints seek the implementation of multiple corporate governance and internal policy changes. On February 2, 2022, the cases were consolidated under the caption In re Emergent BioSolutions, Inc. Derivative Litigation, C.A. No. 2021-0974-MTZ with the institutional investors as co-lead plaintiffs. On March 4, 2022, the defendants’ filed a motion to dismiss the complaint. Ruling on this motion is stayed pursuant to a March 29, 2022 order staying all proceedings pending a final, non-appealable judgment in the Federal Securities Class Action. On December 3, 2021, December 22, 2021 and January 18, 2022, putative shareholder derivative lawsuits were filed by Zachary Elton, Eric White and Jeffrey Reynolds in the Circuit Court for Montgomery County, Maryland on behalf of the Company against certain of its current and former officers and directors for breach of fiduciary duty, unjust enrichment, waste of corporate assets, failing to maintain internal controls, making or causing to be made false and/or misleading statements and material omissions, insider trading and otherwise violating the federal securities laws, each allegation related to the CDMO Manufacturing Capabilities. The complaints seek monetary and punitive damages. On February 22, 2022, the Court entered an order consolidating these actions under case number C-15-21-CV-000496. On March 9, 2022, the parties filed a Joint Stipulation of Stay of Proceedings and Discovery, pursuant to which the parties agreed to stay all proceedings until 30 calendar days after a ruling on the defendants’ motion to dismiss, and on November 2, 2023 the Court approved the parties' joint stipulation to extend the stay of the proceedings and discovery until the close of fact discovery in the Federal Securities Class Action. In addition to the above actions, the Company has received inquiries and subpoenas to produce documents related to these matters from the Department of Justice, the SEC, the Maryland Attorney General’s Office, and the New York Attorney General’s Office. The Company produced or is producing documents as required in response and will continue to cooperate with these government inquiries. The Company also received inquiries and subpoenas from Representative Carolyn Maloney and Representative Jim Clyburn, members of the House Committee on Oversight and Reform and the Select Subcommittee on the Coronavirus Crisis and Senator Murray of the Committee on Health, Education, Labor and Pensions. The Company produced documents and provided testimony and briefings as requested in response to these inquiries.

Segment information

Segment information	9 Months Ended
	Sep. 30, 2023
Segment Reporting [Abstract]
Segment information	Segment information The Company reports segment information based on the internal reporting used by management for making decisions and assessing performance. We manage our business with a focus on two reportable segments. Our Products segment, which includes the Anthrax - MCM products, NARCAN ® products, Smallpox - MCM products and Other products, and our Services segment consisting of our CDMO services. The Company evaluates the performance of these reportable segments based on revenue and Adjusted Gross Margin, which is a non-GAAP financial measure. Segment revenue includes external customer sales, but it does not include inter-segment services. The Company defines Adjusted Gross Margin as segment revenue less segment cost of sales reduced for significant restructuring events, inventory step-up provisions and changes in fair value of contingent consideration. The Company does not allocate research and development, selling, general and administrative costs, amortization of intangibles assets, interest and other income (expense) or taxes to operating segments in the management reporting reviewed by the chief operating decision maker ("CODM"). The accounting policies for segment reporting are the same as for the Company as a whole. The Company manages its assets on a total company basis, not by operating segment, as the Company's operating assets are shared or commingled. Therefore, the Company's CODM does not regularly review any asset information by operating segment and, accordingly, the Company does not report asset information by operating segment. The following table includes segment revenues and a reconciliation of the Company's segment adjusted gross margin to the consolidated statement of operations for each of the Company's reporting segments: Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 (As Restated) (As Restated) Revenues: Products $ 249.8 $ 186.2 $ 695.4 $ 660.5 Services 14.2 36.3 57.7 92.5 Total segment revenues 264.0 222.5 753.1 753.0 Contracts and grants revenues 6.5 17.4 19.6 34.3 Total revenues $ 270.5 $ 239.9 $ 772.7 $ 787.3 Less: Cost of sales: Cost of Products $ 132.5 $ 85.2 $ 368.6 256.8 Cost of Services 44.3 62.0 151.7 215.8 Total cost of sales $ 176.8 $ 147.2 $ 520.3 $ 472.6 Products gross margin $ 117.3 $ 101.0 $ 326.8 $ 403.7 Services gross margin $ (30.1) $ (25.7) $ (94.0) $ (123.3) Consolidated gross margin (1) $ 87.2 $ 75.3 $ 232.8 $ 280.4 Adjustments to gross margin: Products: Changes in fair value of contingent consideration $ (1.1) $ 0.6 $ (0.4) $ 2.4 Restructuring costs 5.0 — 7.0 — Inventory step-up provision — — 1.9 — Services: Restructuring costs $ 8.1 $ — $ 8.1 $ — Products adjusted gross margin $ 121.2 $ 101.6 $ 335.3 $ 406.1 Services adjusted gross margin $ (22.0) $ (25.7) $ (85.9) $ (123.3) Consolidated adjusted gross margin (2) $ 99.2 $ 75.9 $ 249.4 $ 282.8 Other reconciling items: Contracts and grants revenue $ 6.5 $ 17.4 $ 19.6 $ 34.3 Adjustments to gross margin (12.0) (0.6) (16.6) (2.4) Goodwill impairment (218.2) — (218.2) — Impairment of long-lived assets — — (306.7) — Research and development (15.3) (42.2) (82.0) (141.3) Selling, general and administrative (86.0) (81.8) (278.7) (246.1) Amortization of intangible assets (16.3) (14.0) (49.4) (42.0) Interest expense (19.7) (8.5) (66.2) (24.5) Gain on sale of business (0.7) — 74.2 — Other, net (3.4) (13.4) (2.1) (18.4) Loss before income taxes $ (265.9) $ (67.2) $ (676.7) $ (157.6) (1) Total segment revenues less total cost of sales. (2) Consolidated gross margin plus adjustments to gross margin. The following table includes depreciation expense for each segment: Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 (As Restated) (As Restated) Depreciation: Products $ 7.4 $ 11.5 $ 22.9 $ 25.6 Services 3.4 5.5 19.7 34.1 Other 0.9 3.3 3.5 5.7 Total $ 11.7 $ 20.3 $ 46.1 $ 65.4

Adjustments to quarterly financ

Adjustments to quarterly financial data	9 Months Ended
	Sep. 30, 2023
Accounting Changes and Error Corrections [Abstract]
Adjustments to quarterly financial data	Adjustments to quarterly financial data As part of the Company's quarterly review process related to the preparation of its unaudited condensed consolidated financial statements for the three and nine months ended September 30, 2023, the Company determined that its net state deferred tax liability was overstated as of December 31, 2022, resulting in an understatement of the income tax benefits reflected on the Company's consolidated statement of operations. This material error was associated with the use of incorrect state tax rates in the calculation of state deferred tax assets and related valuation allowances, which are non-cash items that resulted in an understatement of the Company's income tax benefit. Refer to Amendment No. 1 to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed with the Securities and Exchange Commission on December 11, 2023 for more information regarding the restatement of the consolidated financial statements for the fiscal year ended December 31, 2022, contained in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2022 (the “Original Form 10-K”). Due to the use of incorrect state tax rates in the calculation of state deferred tax assets and related valuation allowances along with other individually immaterial adjustments affecting the period, the Company understated the income tax provision by $8.1 million and $1.7 million for the three and nine months ended September 30, 2022. As a result, the Company determined to restate its interim financial statements for the three and nine months ended September 30, 2022. In addition to adjustments that impacted the Company’s financial statements for the fiscal year ended December 31, 2022, and interim financial statements as of and for the three and nine months ended September 30, 2022, there were other immaterial adjustments, both individually and in the aggregate, that impacted the Company’s 2023 quarterly filings for the periods ended March 31, 2023 and June 30, 2023. The tables below present the impact of the financial statement adjustments on the Company's previously reported Condensed Consolidated Balance Sheets as of September 30, 2022 and December 31, 2022, the Condensed Consolidated Statement of Operations for the three and nine months ended September 30, 2022 and the Condensed Consolidated Statement of Cash Flows for the nine months ended September 30, 2022. The "Previously Reported" amounts in the following tables are amounts derived from the Original Form 10-K or the Quarterly Report on Form 10-Q for the applicable period. The amounts in the columns labeled "Tax Adjustments" represent the effect of adjustments resulting from the correction of the misstatement of the Company’s net state deferred tax liability and the income tax benefits and includes the tax impact of all other individually immaterial non-tax adjustments. The amounts in the columns labeled "Other Adjustments" represent the effect of correcting other unrelated errors that were previously recognized as out-of-period adjustments in previously filed financial statements that were not material, individually or in the aggregate, to those financial statements. The effects of the restatement and immaterial revisions have been corrected in all impacted tables and footnotes throughout these condensed consolidated financial statements. consolidated financial statements. The following tables present the impact of the financial statement adjustments on the Company's previously reported Condensed Consolidated Balance Sheets as of September 30, 2022 and December 31, 2022: As of September 30, 2022 Previously Reported Tax Adjustments Other Adjustments As Restated ASSETS Current assets: Cash and cash equivalents $ 240.9 $ — $ — $ 240.9 Restricted cash 0.1 — — 0.1 Accounts receivable, net 191.3 — (2.1) 189.2 Inventories, net 546.3 — (18.1) 528.2 Prepaid expenses and other current assets 139.9 — — 139.9 Total current assets 1,118.5 — (20.2) 1,098.3 Property, plant and equipment, net 806.7 — 0.1 806.8 Intangible assets, net 722.7 — 2.2 724.9 Goodwill 224.9 — — 224.9 Other assets 35.7 — 5.1 40.8 Total assets $ 2,908.5 $ — $ (12.8) $ 2,895.7 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 103.8 $ — $ (2.8) $ 101.0 Accrued expenses 35.9 — (0.2) 35.7 Accrued compensation 82.5 — — 82.5 Debt, current portion 21.2 — — 21.2 Other current liabilities 25.0 (0.7) (0.3) 24.0 Total current liabilities 268.4 (0.7) (3.3) 264.4 Debt, net of current portion 1,032.1 — — 1,032.1 Deferred tax liability 113.8 0.1 — 113.9 Other liabilities 44.9 6.5 0.9 52.3 Total liabilities 1,459.2 5.9 (2.4) 1,462.7 Stockholders’ equity: Preferred stock, $0.001 par value; 15.0 shares authorized, no shares issued and outstanding — — — — Common stock, $0.001 par value; 200.0 shares authorized, 55.5 shares issued; 49.9 shares outstanding 0.1 — — 0.1 Treasury stock, at cost, 5.6 common shares (227.7) — — (227.7) Additional paid-in capital 860.1 — — 860.1 Accumulated other comprehensive income (loss), net (5.2) — — (5.2) Retained earnings 822.0 (5.9) (10.4) 805.7 Total stockholders’ equity 1,449.3 (5.9) (10.4) 1,433.0 Total liabilities and stockholders’ equity $ 2,908.5 $ — $ (12.8) $ 2,895.7 As of December 31, 2022 Previously Reported Tax Adjustments Other Adjustments As Restated ASSETS Current assets: Cash and cash equivalents $ 642.6 $ — $ — $ 642.6 Restricted cash — — — — Accounts receivable, net 158.4 — 0.8 159.2 Inventories, net 351.8 — (1.1) 350.7 Prepaid expenses and other current assets 57.9 — — 57.9 Total current assets 1,210.7 — (0.3) 1,210.4 Property, plant and equipment, net 817.6 — — 817.6 Intangible assets, net 728.8 — — 728.8 Goodwill 218.2 — — 218.2 Other assets 191.3 — — 191.3 Total assets $ 3,166.6 $ — $ (0.3) $ 3,166.3 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 103.5 $ — $ — $ 103.5 Accrued expenses 34.9 — — 34.9 Accrued compensation 88.3 — (1.0) 87.3 Debt, current portion 957.3 — — 957.3 Other current liabilities 45.9 (0.3) 0.3 45.9 Total current liabilities 1,229.9 (0.3) (0.7) 1,228.9 Debt, net of current portion 448.5 — — 448.5 Deferred tax liability 71.8 (12.1) — 59.7 Other liabilities 33.4 7.1 1.0 41.5 Total liabilities 1,783.6 (5.3) 0.3 1,778.6 Stockholders’ equity: Preferred stock, $0.001 par value; 15.0 shares authorized, no shares issued and outstanding — — — — Common stock, $0.001 par value; 200.0 shares authorized, 55.7 shares issued; 50.1 shares outstanding 0.1 — — 0.1 Treasury stock, at cost, 5.6 common shares (227.7) — — (227.7) Additional paid-in capital 873.5 — — 873.5 Accumulated other comprehensive income (loss), net 3.1 — — 3.1 Retained earnings 734.0 5.3 (0.6) 738.7 Total stockholders’ equity 1,383.0 5.3 (0.6) 1,387.7 Total liabilities and stockholders’ equity $ 3,166.6 $ — $ (0.3) $ 3,166.3 The following tables present the impact of the financial statement adjustments on the Company's previously reported Quarterly Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2022: Three Months Ended September 30, 2022 Previously Reported Tax Adjustments Other Adjustments As Restated Revenues: Product sales, net $ 186.2 $ — $ — $ 186.2 CDMO: Services 36.2 — (0.1) 36.1 Leases 0.2 — — 0.2 Total CDMO revenues 36.4 — (0.1) 36.3 Contracts and grants 17.4 — — 17.4 Total revenues 240.0 — (0.1) 239.9 Operating expenses: Cost of product sales 85.5 — (0.3) 85.2 Cost of CDMO 63.1 — (1.1) 62.0 Research and development 39.2 — 3.0 42.2 Selling, general and administrative 80.2 — 1.6 81.8 Amortization of intangible assets 14.0 — — 14.0 Total operating expenses 282.0 — 3.2 285.2 Loss from operations (42.0) — (3.3) (45.3) Other income (expense): Interest expense (8.5) — — (8.5) Other, net (13.4) — — (13.4) Total other income (expense), net (21.9) — (21.9) Loss before income taxes (63.9) — (3.3) (67.2) Income tax provision (benefit) 11.8 8.1 — 19.9 Net loss $ (75.7) $ (8.1) $ (3.3) $ (87.1) Net loss per common share Basic $ (1.52) $ (0.16) $ (0.07) $ (1.75) Diluted $ (1.52) $ (0.16) $ (0.07) $ (1.75) Weighted average shares outstanding Basic 49.9 — — 49.9 Diluted 49.9 — — 49.9 Nine Months Ended September 30, 2022 Previously Reported Tax Adjustments Other Adjustments As Restated Revenues: Product sales, net $ 660.5 $ — $ — $ 660.5 CDMO: Services 90.7 — (2.9) 87.8 Leases 4.7 — — 4.7 Total CDMO revenues 95.4 — (2.9) 92.5 Contracts and grants 34.3 — — 34.3 Total revenues 790.2 — (2.9) 787.3 Operating expenses: Cost of product sales 256.8 — — 256.8 Cost of CDMO 217.5 — (1.7) 215.8 Research and development 135.4 — 5.9 141.3 Selling, general and administrative 246.1 — — 246.1 Amortization of intangible assets 42.0 — — 42.0 Total operating expenses 897.8 — 4.2 902.0 Loss from operations (107.6) — (7.1) (114.7) Other income (expense): Interest expense (24.5) — (24.5) Other, net (18.4) — (18.4) Total other income (expense), net (42.9) — — (42.9) Loss before income taxes (150.5) — (7.1) (157.6) Income tax provision (benefit) (14.7) 1.7 — (13.0) Net loss $ (135.8) $ (1.7) $ (7.1) $ (144.6) Net loss per common share Basic $ (2.71) $ (0.03) $ (0.14) $ (2.88) Diluted $ (2.71) $ (0.03) $ (0.14) $ (2.88) Weighted average shares outstanding Basic 50.2 — — 50.2 Diluted 50.2 — — 50.2 The following table presents the impact of the financial statement adjustments on the Company's previously reported Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2022: Nine Months Ended September 30, 2022 Previously Reported Tax Adjustments Other Adjustments As Restated Operating Activities Net loss $ (135.8) $ (1.7) $ (7.1) $ (144.6) Adjustments to reconcile net loss to net cash used in operating activities: Stock-based compensation expense 33.4 — — 33.4 Depreciation and amortization 107.7 — (0.1) 107.6 Change in fair value of contingent obligations, net 2.4 — — 2.4 Amortization of deferred financing costs 3.1 — — 3.1 Deferred income taxes 23.0 2.5 — 25.5 Other 13.0 — — 13.0 Changes in operating assets and liabilities: Accounts receivable 76.2 — 6.3 82.5 Inventories (112.2) — 9.4 (102.8) Prepaid expenses and other assets (29.2) — (5.1) (34.3) Accounts payable (9.0) — (2.8) (11.8) Accrued expenses and other liabilities (47.8) — (0.6) (48.4) Accrued compensation (5.7) — — (5.7) Income taxes receivable and payable, net (50.2) (0.8) — (51.0) Contract liabilities 4.2 — — 4.2 Net cash used in operating activities (126.9) — — (126.9) Investing Activities Purchases of property, plant and equipment (92.2) — — (92.2) Asset acquisitions (243.7) — — (243.7) Net cash used in investing activities (335.9) — — (335.9) Financing Activities Purchases of treasury stock (81.9) — — (81.9) Proceeds from revolving credit facility 238.0 — — 238.0 Principal payments on term loan facility (25.3) — — (25.3) Proceeds from stock-based compensation activity 3.0 — — 3.0 Taxes paid for stock-based compensation activity (5.7) — — (5.7) Net cash provided by financing activities: 128.1 — — 128.1 Effect of exchange rate changes on cash, cash equivalents and restricted cash (0.6) — — (0.6) Net change in cash, cash equivalents and restricted cash (335.3) — — (335.3) Cash, cash equivalents and restricted cash, beginning of period 576.3 — — 576.3 Cash, cash equivalents and restricted cash, end of period $ 241.0 $ — $ — $ 241.0 Supplemental disclosure of cash flow information: Cash paid for interest $ 26.7 $ — $ — $ 26.7 Cash paid for income taxes $ 23.9 $ — $ — $ 23.9 Supplemental information on non-cash investing and financing activities: Purchases of property, plant and equipment unpaid at period end $ 10.0 $ — $ — $ 10.0 Reconciliation of cash and cash equivalents and restricted cash: Cash and cash equivalents $ 240.9 $ — $ — $ 240.9 Restricted cash 0.1 — — 0.1 Total $ 241.0 $ — $ — $ 241.0 The following table presents the impact of the financial statement adjustments on the Company's previously reported Quarterly Condensed Consolidated Statements of Operations for the three months ended March 31, 2022 and June 30, 2022: Three Months Ended Three Months Ended March 31, 2022 June 30, 2022 Previously Reported Tax Adjustments Other Adjustments As Revised Previously Reported Tax Adjustments Other Adjustments As Revised Total revenues $ 307.5 $ — $ (2.7) $ 304.8 $ 242.7 $ — $ (0.1) $ 242.6 Cost of product sales $ 80.3 $ — $ (0.9) $ 79.4 $ 91.0 $ — $ 1.2 $ 92.2 Cost of CDMO $ 75.6 $ — $ (1.6) $ 74.0 $ 78.8 $ — $ 1.0 $ 79.8 Income (loss) from operations $ 6.4 $ — $ 0.5 $ 6.9 $ (72.0) $ — $ (4.3) $ (76.3) Net income (loss) $ (3.7) $ (1.4) $ 0.5 $ (4.6) $ (56.4) $ 7.8 $ (4.3) $ (52.9) Net income (loss) per common share: Basic $ (0.07) $ (0.03) $ 0.01 $ (0.09) $ (1.13) $ 0.16 $ (0.09) $ (1.06) Diluted $ (0.07) $ (0.03) $ 0.01 $ (0.09) $ (1.13) $ 0.16 $ (0.09) $ (1.06) The following table presents the impact of the financial statement adjustments on the Company's previously reported Quarterly Condensed Consolidated Statements of Operations for the three months ended March 31, 2023 and June 30, 2023: Three Months Ended Three Months Ended March 31, 2023 June 30, 2023 Previously Reported Tax Adjustments Other Adjustments As Revised Previously Reported Tax Adjustments Other Adjustments As Revised Total revenues $ 165.1 $ — $ (0.8) $ 164.3 $ 337.9 $ — $ — $ 337.9 Cost of product sales $ 102.9 $ — $ (1.7) $ 101.2 $ 134.9 $ — $ — $ 134.9 Cost of CDMO $ 52.2 $ — $ (0.5) $ 51.7 $ 55.7 $ — $ — $ 55.7 Income (loss) from operations $ (148.1) $ — $ 0.5 $ (147.6) $ (292.9) $ — $ — $ (292.9) Net income (loss) $ (183.0) $ (3.7) $ 0.5 $ (186.2) $ (261.3) $ (0.1) $ — $ (261.4) Net income (loss) per common share: Basic $ (3.65) $ (0.07) $ 0.01 $ (3.71) $ (5.15) $ (0.01) $ — $ (5.16) Diluted $ (3.65) $ (0.07) $ 0.01 $ (3.71) $ (5.15) $ (0.01) $ — $ (5.16)

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Millions	3 Months Ended						9 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2023	Sep. 30, 2022
Pay vs Performance Disclosure
Net loss	$ (263.4)	$ (261.4)	$ (186.2)	$ (87.1)	$ (52.9)	$ (4.6)	$ (711)	$ (144.6)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Sep. 30, 2023
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Summary of significant accoun_2

Summary of significant accounting policies (Policies)	9 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
Basis of presentation and consolidation	The accompanying unaudited condensed consolidated financial statements include the accounts of Emergent and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements included herein have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X issued by the Securities and Exchange Commission ("SEC"). Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in Amendment No. 1 to the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2022, as filed with the SEC on December 11, 2023. In connection with the 2022 adjustments described in Note 18, “Adjustments to quarterly financial data”, there were immaterial adjustments, both individually and in the aggregate, that impacted the Company’s 2023 quarterly filings for the periods ended March 31, 2023 and June 30, 2023. All other adjustments contained in the accompanying unaudited condensed consolidated financial statements are of a normal recurring nature and are necessary to present fairly the financial position of the Company as of September 30, 2023. Interim results are not necessarily indicative of results that may be expected for any other interim period or for an entire year.
Revenue recognition	Beginning in the third quarter of 2023, the Company launched the over-the-counter NARCAN ® (naloxone HCl) Nasal Spray, 4mg (“NARCAN ® OTC”), which was approved by the FDA as an over-the-counter emergency treatment of opioid overdose, broadening our customer base and sales channels to retail pharmacies and digital commerce websites. Refer to Note 13, "Revenue recognition" for more information regarding revenue recognition accounting policies related to NARCAN ® OTC product sales. The Company's NARCAN ® OTC customer contracts are fixed price contracts. The Company invoices and records revenue when the pharmacies and wholesalers receive product from the third-party logistics warehouse used by the Company, which is the point at which control is transferred to the customer. Revenues for NARCAN ® OTC are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established. Estimates of variable consideration includes allowance for returns, specialty distributor fees, wholesaler fees and prompt payment discounts. Revenues from NARCAN ® OTC are recognized to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with such variable consideration is subsequently resolved. The Company considers several factors in the estimation process for the allowance for returns of NARCAN ® OTC, including inventory levels within the distribution channel, product shelf life and historical return activity, including activity for product sold for which the return period has passed, as well as other relevant factors. Because returned product cannot be resold, there is no corresponding asset for product returns.
Pre-launch inventory	Within the Company's Products segment, costs relating to raw materials and production of inventory in preparation for product launch prior to regulatory approval are capitalized when the review process has progressed to a point where objective and persuasive evidence exists that regulatory approval is probable, the future economic benefit is expected to be realized, and the Company believes that material uncertainties related to the ultimate regulatory approval have been significantly reduced. Pre-launch inventory is recorded to research and development expense unless these criteria are met. For pre-launch inventory that is capitalized, the Company considers a number of specific facts and circumstances, including the product candidate’s current status in the drug development and regulatory approval process, results from related clinical trials, results from meetings with relevant regulatory agencies prior to the filing of regulatory applications, potential obstacles to the approval process, historical experience, viability of commercialization and market trends. This policy is not applicable to pre-launch inventory purchased to satisfy a performance obligation related to a CDMO contract as CDMO pre-launch inventory may be capitalized if it has future economic benefit based on the terms of the contract.
Fair value measurements	Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability, an exit price, in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value, includes: Level 1 — Observable inputs for identical assets or liabilities such as quoted prices in active markets; Level 2 — Inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3 — Unobservable inputs in which little or no market data exists, which are therefore developed by the Company using estimates and assumptions that reflect those that a market participant would use. On a recurring basis, the Company measures and records money market funds (Level 1), interest-rate swap arrangements and time deposits (Level 2) and contingent purchase consideration (Level 3) using fair value measurements in the accompanying financial statements. The carrying amounts of the Company's short-term financial instruments, which include cash and cash equivalents, accounts receivable and accounts payable approximate their fair values due to their short maturities. The carrying amounts of the Company’s long-term variable interest rate debt arrangements (Level 2) approximate their fair values.
Derivatives	The valuation of the interest rate swaps is determined using widely accepted valuation techniques, including discounted cash flow analysis on the expected cash flows of each interest rate swap. This analysis reflects the contractual terms of the interest rate swaps, including the period to maturity, and uses observable market-based inputs, including interest rate curves and implied volatilities. The fair values of interest rate swaps are determined using the market standard methodology of netting the discounted future fixed cash payments (or receipts) and the discounted expected variable cash receipts (or payments). The variable cash payments (or receipts) are based on an expectation of future interest rates (forward curves) derived from observable market interest rate curves. We incorporate credit valuation adjustments in the fair value measurements to appropriately reflect both our own nonperformance risk and the respective counterparty’s nonperformance risk. These credit valuation adjustments were not significant inputs for the fair value calculations for the periods presented. In adjusting the fair value of our derivative contracts for the effect of nonperformance risk, we have considered the impact of netting and any applicable credit enhancements, such as the posting of collateral, thresholds, mutual puts and guarantees. The valuation of interest rate swaps fall into Level 2 in the fair value hierarchy.
Segment Information	The Company reports segment information based on the internal reporting used by management for making decisions and assessing performance. We manage our business with a focus on two reportable segments. Our Products segment, which includes the Anthrax - MCM products, NARCAN ® products, Smallpox - MCM products and Other products, and our Services segment consisting of our CDMO services. The Company evaluates the performance of these reportable segments based on revenue and Adjusted Gross Margin, which is a non-GAAP financial measure. Segment revenue includes external customer sales, but it does not include inter-segment services. The Company defines Adjusted Gross Margin as segment revenue less segment cost of sales reduced for significant restructuring events, inventory step-up provisions and changes in fair value of contingent consideration. The Company does not allocate research and development, selling, general and administrative costs, amortization of intangibles assets, interest and other income (expense) or taxes to operating segments in the management reporting reviewed by the chief operating decision maker ("CODM"). The accounting policies for segment reporting are the same as for the Company as a whole.

Long-lived asset impairment a_2

Long-lived asset impairment and restructuring charges (Tables)	9 Months Ended
	Sep. 30, 2023
Restructuring and Related Activities [Abstract]
Schedule of Impairment of Long-Lived Assets Held and Used by Asset	The table below presents the total impairment charge by asset class for the three and nine months ended September 30, 2023: Three Months Ended September 30, 2023 Nine Months Ended September 30, 2023 Buildings, building improvements and leasehold improvements $ — $ 81.5 Furniture and equipment — 117.5 Software — 0.3 Construction-in-progress — 107.4 Total impairment of long-lived assets $ — $ 306.7
Schedule of Restructuring and Related Costs	The following table presents the total restructuring costs associated with the Company’s segments as well as unallocated corporate and research and development ("R&D") charges for the three and nine months ended September 30, 2023: Three Months Ended Nine Months Ended Products $ 5.0 $ 7.0 Services 8.1 8.1 Total restructuring costs by segment 13.1 15.1 Corporate 6.3 11.4 R&D $ 0.9 3.4 Total restructuring costs $ 20.3 $ 29.9 The following table presents the total restructuring costs, by function, for the three and nine months ended September 30, 2023: Three Months Ended Nine Months Ended Employee transition $ 0.3 $ 0.6 Severance payments 17.9 26.6 Employee benefits 2.1 2.7 Total restructuring costs $ 20.3 $ 29.9
Schedule of Restructuring Reserve by Type of Cost	The following table provides the components of and changes in the Company's restructuring accrual for the January 2023 Plan during the three and nine months ended September 30, 2023: Employee Transition Severance Payments Employee Benefits Total Balance at December 31, 2022 $ — $ — $ — $ — Accruals 0.3 8.7 0.7 9.7 Cash payments (0.2) (2.0) (0.1) (2.3) Balance at March 31, 2023 $ 0.1 $ 6.7 $ 0.6 $ 7.4 Accruals — 0.1 (0.2) (0.1) Cash payments — (3.6) (0.1) (3.7) Balance at June 30, 2023 $ 0.1 $ 3.2 $ 0.3 $ 3.6 Accruals — — (0.2) (0.2) Cash payments — (1.1) — (1.1) Balance at September 30, 2023 $ 0.1 $ 2.1 $ 0.1 $ 2.3 The following table provides the components of and changes in the Company's restructuring accrual for the August 2023 Plan during the three and nine months ended September 30, 2023: Employee Transition Severance Payments Employee Benefits Total Balance at December 31, 2022 $ — $ — $ — $ — Accruals — — — — Cash payments — — — — Balance at March 31, 2023 $ — $ — $ — $ — Accruals — — — — Cash payments — — — — Balance at June 30, 2023 $ — $ — $ — $ — Accruals 0.3 17.9 2.3 20.5 Cash payments (0.2) (1.7) — (1.9) Balance at September 30, 2023 $ 0.1 $ 16.2 $ 2.3 $ 18.6

Inventories, net (Tables)

Inventories, net (Tables)	9 Months Ended
	Sep. 30, 2023
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventories, net consisted of the following: September 30, 2023 December 31, 2022 (As Restated) Raw materials and supplies $ 142.3 $ 142.3 Work-in-process 146.3 116.2 Finished goods 65.5 92.2 Total inventories, net $ 354.1 $ 350.7

Property, plant and equipment_2

Property, plant and equipment, net (Tables)	9 Months Ended
	Sep. 30, 2023
Property Plant and Equipment Income Statement Disclosures [Abstract]
Schedule of Property, Plant and Equipment	Property, plant and equipment, net consisted of the following: September 30, 2023 (1) December 31, 2022 Land and improvements $ 30.0 $ 54.9 Buildings, building improvements and leasehold improvements 228.9 327.9 Furniture and equipment 428.5 567.5 Software 64.0 65.6 Construction-in-progress 44.9 185.5 Property, plant and equipment, gross $ 796.3 $ 1,201.4 Less: Accumulated depreciation & amortization (400.9) (383.8) Total property, plant and equipment, net $ 395.4 $ 817.6 (1) During the nine months ended September 30, 2023, the Company recorded a non-cash impairment charge of $306.7 million related to certain CDMO long-lived assets. See Note 4, "Long-lived asset impairment and restructuring charges" for more details regarding the impairment charge.

Intangible assets and goodwill

Intangible assets and goodwill (Tables)	9 Months Ended
	Sep. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Finite-Lived Intangible Assets	The following table summarizes the Company's finite-lived intangible assets: Weighted Average Useful Life in Years September 30, 2023 December 31, 2022 Gross Carrying Amount Accumulated Amortization Net Carrying Amount (1) Gross Carrying Amount Accumulated Amortization Net Carrying Amount Products (2) 13.5 $ 855.4 $ 272.6 $ 582.8 $ 982.1 $ 253.3 $ 728.8 Customer relationships 0.0 28.6 28.6 — 28.6 28.6 — CDMO 0.0 5.5 5.5 — 5.5 5.5 — Total intangible assets $ 889.5 $ 306.7 $ 582.8 $ 1,016.2 $ 287.4 $ 728.8 (1) During the nine months ended September 30, 2023, the Company sold $102.9 million of intangible assets, net as part of the sale of its travel health business to Bavarian Nordic. See Note 3, "Divestiture" for more information on the sale of the travel health business. (2) During the three months ended September 30, 2023, the Company recorded a $6.3 million intangible asset addition related to the contingent consideration payment to Ridgeback for the award of a 10-year contract by the Biomedical Advanced Research and Development Authority for advanced development, manufacturing scale-up, and procurement of Ebanga TM treatment for Ebola. The related intangible asset was acquired through an asset acquisition that was completed in 2022.
Schedule of Finite-lived Intangible Assets Amortization Expense	Amortization expense associated with the Company's intangible assets was recorded as follows: Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Amortization expense $ 16.3 $ 14.0 $ 49.4 $ 42.0
Schedule of Goodwill	The table below summarizes the changes in the carrying amount of goodwill by reportable segment: Products (1) Services (2) Total Balance at December 31, 2022 $ 218.2 $ — $ 218.2 Goodwill impairment (218.2) — (218.2) Balance at September 30, 2023 $ — $ — $ — (1) Amounts for the Company's Products segment include gross carrying values of $259.9 million as of September 30, 2023 and December 31, 2022 and accumulated impairment losses of $259.9 million. (2) Amounts for the Company's Services segment include gross carrying values of $6.7 million as of September 30, 2023 and December 31, 2022, and accumulated impairment losses of $6.7 million.

Fair value measurements (Tables

Fair value measurements (Tables)	9 Months Ended
	Sep. 30, 2023
Fair Value Disclosures [Abstract]
Schedule of Fair Value Hierarchy of Assets and Liabilities	The table below presents information about the Company's assets and liabilities that are regularly measured and carried at fair value and indicates the level within the fair value hierarchy of the valuation techniques the Company utilized to determine fair value: September 30, 2023 December 31, 2022 (As Restated) Total Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Assets: Money market accounts $ 37.2 $ 37.2 $ — $ — $ 320.8 $ 320.8 $ — $ — Time deposits — — — — 170.7 — 170.7 — Derivative instruments — — — — 8.5 — 8.5 — Total $ 37.2 $ 37.2 $ — $ — $ 500.0 $ 320.8 $ 179.2 $ — Liabilities: Contingent consideration $ 5.4 $ — $ — $ 5.4 $ 8.0 $ — $ — $ 8.0 Total $ 5.4 $ — $ — $ 5.4 $ 8.0 $ — $ — $ 8.0
Schedule of Contingent Consideration Roll Forward	The table below is a reconciliation of the beginning and ending balance of the Company's Level 3 contingent consideration liability: Contingent Consideration Balance at December 31, 2022 (As Restated) $ 8.0 Change in fair value 0.3 Settlements (0.7) Balance at March 31, 2023 $ 7.6 Change in fair value 0.4 Settlements (0.6) Balance at June 30, 2023 $ 7.4 Change in fair value (1.1) Settlements (0.9) Balance at September 30, 2023 $ 5.4
Schedule of Fair Value Level 3 of Significant Unobservable Inputs	The recurring Level 3 fair value measurement for the Company's contingent consideration liability used the following significant unobservable inputs: Contingent Consideration Liability Fair Value as of September 30, 2023 Valuation Technique Unobservable Input Range Royalty based $5.4 million Discounted cash flow Discount rate 10.4% Probability of payment 0% - 75% Projected year of payment 2023 - 2028

Derivative instruments and he_2

Derivative instruments and hedging activities (Tables)	9 Months Ended
	Sep. 30, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value	The table below presents the fair value of the Company’s derivative financial instruments designated as hedges as well as their classification on the Condensed Consolidated Balance Sheets: Fair Value of Asset Derivatives Classification September 30, 2023 December 31, 2022 Interest Rate Swaps Other Current Assets $ — $ 8.5
Schedule of Derivative Instruments, Gain (Loss)	The following table summarizes the amount of gains or losses reclassified from "Accumulated other comprehensive income (loss), net" into "Interest expense" on the Condensed Consolidated Statement of Operations during the three and nine months ended September 30, 2023 and 2022: Classification Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Interest rate swaps gain (loss) Interest expense $ 3.1 $ 0.4 $ 8.4 $ (1.9)

Debt (Tables)

Debt (Tables)	9 Months Ended
	Sep. 30, 2023
Debt Disclosure [Abstract]
Schedule of Debt	The table below presents the components of the Company’s debt: September 30, 2023 December 31, 2022 Senior secured credit agreement - Term loan due 2025 $ 202.1 $ 362.8 Senior secured credit agreement - Revolver loan due 2025 211.2 598.0 3.875% Senior Unsecured Notes due 2028 450.0 450.0 Other 3.0 3.0 Total debt $ 866.3 $ 1,413.8 Less: Unamortized debt issuance costs (1) (4.5) (8.0) Less: Current portion of long-term debt, net (413.6) (957.3) Non-current portion of debt, net $ 448.2 $ 448.5 (1) As of September 30, 2023, excludes the unamortized debt issuance costs related to the revolver loan which are included within "Other current assets" on the accompanying Condensed Consolidated Balance Sheet.

Stock-based compensation and _2

Stock-based compensation and stockholders' equity (Tables)	9 Months Ended
	Sep. 30, 2023
Stockholders' Equity Note [Abstract]
Schedule of Stock-based Compensation Expense	Stock-based compensation expense, net of forfeitures was recorded in the following financial statement line items: Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Cost of product sales $ 1.0 $ 1.8 $ 3.6 $ 5.4 Cost of CDMO 0.2 0.4 0.8 1.4 R&D 0.6 1.3 1.7 3.9 Selling, general and administrative 2.2 7.7 13.0 22.7 Total stock-based compensation expense $ 4.0 $ 11.2 $ 19.1 $ 33.4
Schedule of Accumulated Other Comprehensive Income (Loss)	The following table includes changes in accumulated other comprehensive income (loss), net of tax by component: Defined Benefit Pension Plan Derivative Instruments Foreign Currency Total Balance at December 31, 2022 $ 3.5 $ 6.2 $ (6.6) $ 3.1 Other comprehensive income (loss) before reclassifications — (4.4) (0.1) (4.5) Amounts reclassified from accumulated other comprehensive income (loss) — 2.4 — 2.4 Net current period other comprehensive income (loss) — (2.0) (0.1) (2.1) Balance at March 31, 2023 $ 3.5 $ 4.2 $ (6.7) $ 1.0 Other comprehensive income (loss) before reclassifications — 1.2 2.6 3.8 Amounts reclassified from accumulated other comprehensive income (loss) (3.5) (2.9) — (6.4) Net current period other comprehensive income (loss) (3.5) (1.7) 2.6 (2.6) Balance at June 30, 2023 $ — $ 2.5 $ (4.1) $ (1.6) Other comprehensive income (loss) before reclassifications — 0.9 1.2 2.1 Amounts reclassified from accumulated other comprehensive income (loss) — (3.1) — (3.1) Net current period other comprehensive income (loss) — (2.2) 1.2 (1.0) Balance at September 30, 2023 $ — $ 0.3 $ (2.9) $ (2.6) Balance at December 31, 2021 $ (4.0) $ (4.5) $ (7.6) $ (16.1) Other comprehensive income (loss) before reclassifications — 4.9 0.5 5.4 Amounts reclassified from accumulated other comprehensive income (loss) — 1.4 — 1.4 Net current period other comprehensive income (loss) — 6.3 0.5 6.8 Balance at March 31, 2022 $ (4.0) $ 1.8 $ (7.1) $ (9.3) Other comprehensive income (loss) before reclassifications — 1.9 0.4 2.3 Amounts reclassified from accumulated other comprehensive income (loss) — 0.9 — 0.9 Net current period other comprehensive income (loss) — 2.8 0.4 3.2 Balance at June 30, 2022 $ (4.0) $ 4.6 $ (6.7) $ (6.1) Other comprehensive income (loss) before reclassifications — 2.6 (1.3) 1.3 Amounts reclassified from accumulated other comprehensive income (loss) — (0.4) — (0.4) Net current period other comprehensive income (loss) — 2.2 (1.3) 0.9 Balance at September 30, 2022 $ (4.0) $ 6.8 $ (8.0) $ (5.2)
Schedule of Comprehensive Income (Loss)	The tables below present the tax effects related to each component of other comprehensive income (loss): Three Months Ended September 30, 2023 2022 Pretax Tax Expense Net of tax Pretax Tax Expense Net of tax Defined benefit pension plan $ — $ — $ — $ — $ — $ — Derivative instruments (3.1) 0.9 (2.2) 3.0 (0.8) 2.2 Foreign currency translation adjustments 0.9 0.3 1.2 0.1 (1.4) (1.3) Total adjustments $ (2.2) $ 1.2 $ (1.0) $ 3.1 $ (2.2) $ 0.9 Nine Months Ended September 30, 2023 2022 Pretax Tax Expense Net of tax Pretax Tax Expense Net of tax Defined benefit pension plan $ (4.1) $ 0.6 $ (3.5) $ — $ — $ — Derivative instruments (8.0) 2.1 (5.9) 15.4 (4.1) 11.3 Foreign currency translation adjustments 2.9 0.8 3.7 2.1 (2.5) (0.4) Total adjustments $ (9.2) $ 3.5 $ (5.7) $ 17.5 $ (6.6) $ 10.9

Loss per common share (Tables)

Loss per common share (Tables)	9 Months Ended
	Sep. 30, 2023
Earnings Per Share [Abstract]
Schedule of Basic and Diluted Net Loss per Common Share	The following table presents the calculation of basic and diluted loss per common share: Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 (As Restated) (As Restated) Numerator: Net loss $ (263.4) $ (87.1) $ (711.0) $ (144.6) Denominator: Weighted-average number of shares outstanding-basic 51.8 49.9 50.9 50.2 Weighted-average number of shares outstanding-diluted 51.8 49.9 50.9 50.2 Loss per common share - basic $ (5.08) $ (1.75) $ (13.97) $ (2.88) Loss per common share - diluted $ (5.08) $ (1.75) $ (13.97) $ (2.88) Anti-dilutive securities 4.0 3.3 3.6 2.6

Revenue recognition (Tables)

Revenue recognition (Tables)	9 Months Ended
	Sep. 30, 2023
Revenue from Contract with Customer [Abstract]
Schedule of Disaggregation of Revenue	The Company's revenues disaggregated by operating segment and major sources for the three and nine months ended September 30, 2023 and 2022 were as follows: Three Months Ended September 30, 2023 Three Months Ended September 30, 2022 USG Non-USG Total USG Non-USG Total Product sales, net $ 103.0 $ 146.8 $ 249.8 $ 33.4 $ 152.8 $ 186.2 CDMO: Services — 13.2 13.2 — 36.1 36.1 Leases — 1.0 1.0 — 0.2 0.2 Total CDMO $ — $ 14.2 $ 14.2 $ — $ 36.3 $ 36.3 Contracts and grants 5.1 1.4 6.5 16.4 1.0 17.4 Total revenues $ 108.1 $ 162.4 $ 270.5 $ 49.8 $ 190.1 $ 239.9 Nine Months Ended September 30, 2023 Nine Months Ended September 30, 2022 USG Non-USG Total USG Non-USG Total Product sales, net $ 279.6 $ 415.8 $ 695.4 $ 255.0 $ 405.5 $ 660.5 CDMO: Services — 52.2 52.2 — 87.8 87.8 Leases — 5.5 5.5 — 4.7 4.7 Total CDMO $ — $ 57.7 $ 57.7 $ — $ 92.5 $ 92.5 Contracts and grants 14.6 5.0 19.6 31.7 2.6 34.3 Total revenues $ 294.2 $ 478.5 $ 772.7 $ 286.7 $ 500.6 $ 787.3
Schedule of Rollforward of Contract Liabilities	The following table presents the roll forward of the contract liability balances: Contract Liabilities Balance at December 31, 2022 $ 31.7 Balance at September 30, 2023 $ 27.9 Revenue recognized in the period from amounts included in contract liability at the beginning of the period: $ (7.3)
Schedule of Accounts Receivable, Net	Accounts receivable, including unbilled accounts receivable contract assets, consist of the following: September 30, 2023 December 31, 2022 (As Restated) Accounts receivable: Billed $ 156.6 $ 102.7 Unbilled 61.0 57.2 Allowance for expected credit losses (1.1) (0.7) Accounts receivable, net $ 216.5 $ 159.2

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2023
Leases [Abstract]
Schedule of Components of Lease Expense	The components of lease expense were as follows: Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Operating lease cost: Amortization of right-of-use assets $ 1.1 $ 1.4 $ 3.1 $ 4.2 Interest on lease liabilities 0.2 0.3 0.6 0.8 Total operating lease cost $ 1.3 $ 1.7 $ 3.7 $ 5.0
Schedule of Leases Supplemental Balance Sheets	Supplemental balance sheet information related to lessee activities is as follows: Leases Classification September 30, 2023 December 31, 2022 Operating lease right-of-use assets Other assets $ 17.1 $ 19.4 Operating lease liabilities, current portion Other current liabilities $ 3.5 $ 5.8 Operating lease liabilities Other liabilities 14.6 14.8 Total operating lease liabilities $ 18.1 $ 20.6 Operating leases: Weighted average remaining lease term (years) 6.3 5.9 Weighted average discount rate 5.2 % 4.1 %

Segment information (Tables)

Segment information (Tables)	9 Months Ended
	Sep. 30, 2023
Segment Reporting [Abstract]
Schedule of Reconciliation of Operating Profit (Loss) from Segments to Consolidated	The following table includes segment revenues and a reconciliation of the Company's segment adjusted gross margin to the consolidated statement of operations for each of the Company's reporting segments: Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 (As Restated) (As Restated) Revenues: Products $ 249.8 $ 186.2 $ 695.4 $ 660.5 Services 14.2 36.3 57.7 92.5 Total segment revenues 264.0 222.5 753.1 753.0 Contracts and grants revenues 6.5 17.4 19.6 34.3 Total revenues $ 270.5 $ 239.9 $ 772.7 $ 787.3 Less: Cost of sales: Cost of Products $ 132.5 $ 85.2 $ 368.6 256.8 Cost of Services 44.3 62.0 151.7 215.8 Total cost of sales $ 176.8 $ 147.2 $ 520.3 $ 472.6 Products gross margin $ 117.3 $ 101.0 $ 326.8 $ 403.7 Services gross margin $ (30.1) $ (25.7) $ (94.0) $ (123.3) Consolidated gross margin (1) $ 87.2 $ 75.3 $ 232.8 $ 280.4 Adjustments to gross margin: Products: Changes in fair value of contingent consideration $ (1.1) $ 0.6 $ (0.4) $ 2.4 Restructuring costs 5.0 — 7.0 — Inventory step-up provision — — 1.9 — Services: Restructuring costs $ 8.1 $ — $ 8.1 $ — Products adjusted gross margin $ 121.2 $ 101.6 $ 335.3 $ 406.1 Services adjusted gross margin $ (22.0) $ (25.7) $ (85.9) $ (123.3) Consolidated adjusted gross margin (2) $ 99.2 $ 75.9 $ 249.4 $ 282.8 Other reconciling items: Contracts and grants revenue $ 6.5 $ 17.4 $ 19.6 $ 34.3 Adjustments to gross margin (12.0) (0.6) (16.6) (2.4) Goodwill impairment (218.2) — (218.2) — Impairment of long-lived assets — — (306.7) — Research and development (15.3) (42.2) (82.0) (141.3) Selling, general and administrative (86.0) (81.8) (278.7) (246.1) Amortization of intangible assets (16.3) (14.0) (49.4) (42.0) Interest expense (19.7) (8.5) (66.2) (24.5) Gain on sale of business (0.7) — 74.2 — Other, net (3.4) (13.4) (2.1) (18.4) Loss before income taxes $ (265.9) $ (67.2) $ (676.7) $ (157.6) (1) Total segment revenues less total cost of sales. (2) Consolidated gross margin plus adjustments to gross margin.
Schedule of Segment Reporting Information, by Segment	The following table includes depreciation expense for each segment: Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 (As Restated) (As Restated) Depreciation: Products $ 7.4 $ 11.5 $ 22.9 $ 25.6 Services 3.4 5.5 19.7 34.1 Other 0.9 3.3 3.5 5.7 Total $ 11.7 $ 20.3 $ 46.1 $ 65.4

Adjustments to quarterly fina_2

Adjustments to quarterly financial data (Tables)	9 Months Ended
	Sep. 30, 2023
Accounting Changes and Error Corrections [Abstract]
Schedule of Error Corrections and Prior Period Adjustments	The following tables present the impact of the financial statement adjustments on the Company's previously reported Condensed Consolidated Balance Sheets as of September 30, 2022 and December 31, 2022: As of September 30, 2022 Previously Reported Tax Adjustments Other Adjustments As Restated ASSETS Current assets: Cash and cash equivalents $ 240.9 $ — $ — $ 240.9 Restricted cash 0.1 — — 0.1 Accounts receivable, net 191.3 — (2.1) 189.2 Inventories, net 546.3 — (18.1) 528.2 Prepaid expenses and other current assets 139.9 — — 139.9 Total current assets 1,118.5 — (20.2) 1,098.3 Property, plant and equipment, net 806.7 — 0.1 806.8 Intangible assets, net 722.7 — 2.2 724.9 Goodwill 224.9 — — 224.9 Other assets 35.7 — 5.1 40.8 Total assets $ 2,908.5 $ — $ (12.8) $ 2,895.7 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 103.8 $ — $ (2.8) $ 101.0 Accrued expenses 35.9 — (0.2) 35.7 Accrued compensation 82.5 — — 82.5 Debt, current portion 21.2 — — 21.2 Other current liabilities 25.0 (0.7) (0.3) 24.0 Total current liabilities 268.4 (0.7) (3.3) 264.4 Debt, net of current portion 1,032.1 — — 1,032.1 Deferred tax liability 113.8 0.1 — 113.9 Other liabilities 44.9 6.5 0.9 52.3 Total liabilities 1,459.2 5.9 (2.4) 1,462.7 Stockholders’ equity: Preferred stock, $0.001 par value; 15.0 shares authorized, no shares issued and outstanding — — — — Common stock, $0.001 par value; 200.0 shares authorized, 55.5 shares issued; 49.9 shares outstanding 0.1 — — 0.1 Treasury stock, at cost, 5.6 common shares (227.7) — — (227.7) Additional paid-in capital 860.1 — — 860.1 Accumulated other comprehensive income (loss), net (5.2) — — (5.2) Retained earnings 822.0 (5.9) (10.4) 805.7 Total stockholders’ equity 1,449.3 (5.9) (10.4) 1,433.0 Total liabilities and stockholders’ equity $ 2,908.5 $ — $ (12.8) $ 2,895.7 As of December 31, 2022 Previously Reported Tax Adjustments Other Adjustments As Restated ASSETS Current assets: Cash and cash equivalents $ 642.6 $ — $ — $ 642.6 Restricted cash — — — — Accounts receivable, net 158.4 — 0.8 159.2 Inventories, net 351.8 — (1.1) 350.7 Prepaid expenses and other current assets 57.9 — — 57.9 Total current assets 1,210.7 — (0.3) 1,210.4 Property, plant and equipment, net 817.6 — — 817.6 Intangible assets, net 728.8 — — 728.8 Goodwill 218.2 — — 218.2 Other assets 191.3 — — 191.3 Total assets $ 3,166.6 $ — $ (0.3) $ 3,166.3 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 103.5 $ — $ — $ 103.5 Accrued expenses 34.9 — — 34.9 Accrued compensation 88.3 — (1.0) 87.3 Debt, current portion 957.3 — — 957.3 Other current liabilities 45.9 (0.3) 0.3 45.9 Total current liabilities 1,229.9 (0.3) (0.7) 1,228.9 Debt, net of current portion 448.5 — — 448.5 Deferred tax liability 71.8 (12.1) — 59.7 Other liabilities 33.4 7.1 1.0 41.5 Total liabilities 1,783.6 (5.3) 0.3 1,778.6 Stockholders’ equity: Preferred stock, $0.001 par value; 15.0 shares authorized, no shares issued and outstanding — — — — Common stock, $0.001 par value; 200.0 shares authorized, 55.7 shares issued; 50.1 shares outstanding 0.1 — — 0.1 Treasury stock, at cost, 5.6 common shares (227.7) — — (227.7) Additional paid-in capital 873.5 — — 873.5 Accumulated other comprehensive income (loss), net 3.1 — — 3.1 Retained earnings 734.0 5.3 (0.6) 738.7 Total stockholders’ equity 1,383.0 5.3 (0.6) 1,387.7 Total liabilities and stockholders’ equity $ 3,166.6 $ — $ (0.3) $ 3,166.3 The following tables present the impact of the financial statement adjustments on the Company's previously reported Quarterly Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2022: Three Months Ended September 30, 2022 Previously Reported Tax Adjustments Other Adjustments As Restated Revenues: Product sales, net $ 186.2 $ — $ — $ 186.2 CDMO: Services 36.2 — (0.1) 36.1 Leases 0.2 — — 0.2 Total CDMO revenues 36.4 — (0.1) 36.3 Contracts and grants 17.4 — — 17.4 Total revenues 240.0 — (0.1) 239.9 Operating expenses: Cost of product sales 85.5 — (0.3) 85.2 Cost of CDMO 63.1 — (1.1) 62.0 Research and development 39.2 — 3.0 42.2 Selling, general and administrative 80.2 — 1.6 81.8 Amortization of intangible assets 14.0 — — 14.0 Total operating expenses 282.0 — 3.2 285.2 Loss from operations (42.0) — (3.3) (45.3) Other income (expense): Interest expense (8.5) — — (8.5) Other, net (13.4) — — (13.4) Total other income (expense), net (21.9) — (21.9) Loss before income taxes (63.9) — (3.3) (67.2) Income tax provision (benefit) 11.8 8.1 — 19.9 Net loss $ (75.7) $ (8.1) $ (3.3) $ (87.1) Net loss per common share Basic $ (1.52) $ (0.16) $ (0.07) $ (1.75) Diluted $ (1.52) $ (0.16) $ (0.07) $ (1.75) Weighted average shares outstanding Basic 49.9 — — 49.9 Diluted 49.9 — — 49.9 Nine Months Ended September 30, 2022 Previously Reported Tax Adjustments Other Adjustments As Restated Revenues: Product sales, net $ 660.5 $ — $ — $ 660.5 CDMO: Services 90.7 — (2.9) 87.8 Leases 4.7 — — 4.7 Total CDMO revenues 95.4 — (2.9) 92.5 Contracts and grants 34.3 — — 34.3 Total revenues 790.2 — (2.9) 787.3 Operating expenses: Cost of product sales 256.8 — — 256.8 Cost of CDMO 217.5 — (1.7) 215.8 Research and development 135.4 — 5.9 141.3 Selling, general and administrative 246.1 — — 246.1 Amortization of intangible assets 42.0 — — 42.0 Total operating expenses 897.8 — 4.2 902.0 Loss from operations (107.6) — (7.1) (114.7) Other income (expense): Interest expense (24.5) — (24.5) Other, net (18.4) — (18.4) Total other income (expense), net (42.9) — — (42.9) Loss before income taxes (150.5) — (7.1) (157.6) Income tax provision (benefit) (14.7) 1.7 — (13.0) Net loss $ (135.8) $ (1.7) $ (7.1) $ (144.6) Net loss per common share Basic $ (2.71) $ (0.03) $ (0.14) $ (2.88) Diluted $ (2.71) $ (0.03) $ (0.14) $ (2.88) Weighted average shares outstanding Basic 50.2 — — 50.2 Diluted 50.2 — — 50.2 The following table presents the impact of the financial statement adjustments on the Company's previously reported Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2022: Nine Months Ended September 30, 2022 Previously Reported Tax Adjustments Other Adjustments As Restated Operating Activities Net loss $ (135.8) $ (1.7) $ (7.1) $ (144.6) Adjustments to reconcile net loss to net cash used in operating activities: Stock-based compensation expense 33.4 — — 33.4 Depreciation and amortization 107.7 — (0.1) 107.6 Change in fair value of contingent obligations, net 2.4 — — 2.4 Amortization of deferred financing costs 3.1 — — 3.1 Deferred income taxes 23.0 2.5 — 25.5 Other 13.0 — — 13.0 Changes in operating assets and liabilities: Accounts receivable 76.2 — 6.3 82.5 Inventories (112.2) — 9.4 (102.8) Prepaid expenses and other assets (29.2) — (5.1) (34.3) Accounts payable (9.0) — (2.8) (11.8) Accrued expenses and other liabilities (47.8) — (0.6) (48.4) Accrued compensation (5.7) — — (5.7) Income taxes receivable and payable, net (50.2) (0.8) — (51.0) Contract liabilities 4.2 — — 4.2 Net cash used in operating activities (126.9) — — (126.9) Investing Activities Purchases of property, plant and equipment (92.2) — — (92.2) Asset acquisitions (243.7) — — (243.7) Net cash used in investing activities (335.9) — — (335.9) Financing Activities Purchases of treasury stock (81.9) — — (81.9) Proceeds from revolving credit facility 238.0 — — 238.0 Principal payments on term loan facility (25.3) — — (25.3) Proceeds from stock-based compensation activity 3.0 — — 3.0 Taxes paid for stock-based compensation activity (5.7) — — (5.7) Net cash provided by financing activities: 128.1 — — 128.1 Effect of exchange rate changes on cash, cash equivalents and restricted cash (0.6) — — (0.6) Net change in cash, cash equivalents and restricted cash (335.3) — — (335.3) Cash, cash equivalents and restricted cash, beginning of period 576.3 — — 576.3 Cash, cash equivalents and restricted cash, end of period $ 241.0 $ — $ — $ 241.0 Supplemental disclosure of cash flow information: Cash paid for interest $ 26.7 $ — $ — $ 26.7 Cash paid for income taxes $ 23.9 $ — $ — $ 23.9 Supplemental information on non-cash investing and financing activities: Purchases of property, plant and equipment unpaid at period end $ 10.0 $ — $ — $ 10.0 Reconciliation of cash and cash equivalents and restricted cash: Cash and cash equivalents $ 240.9 $ — $ — $ 240.9 Restricted cash 0.1 — — 0.1 Total $ 241.0 $ — $ — $ 241.0 The following table presents the impact of the financial statement adjustments on the Company's previously reported Quarterly Condensed Consolidated Statements of Operations for the three months ended March 31, 2022 and June 30, 2022: Three Months Ended Three Months Ended March 31, 2022 June 30, 2022 Previously Reported Tax Adjustments Other Adjustments As Revised Previously Reported Tax Adjustments Other Adjustments As Revised Total revenues $ 307.5 $ — $ (2.7) $ 304.8 $ 242.7 $ — $ (0.1) $ 242.6 Cost of product sales $ 80.3 $ — $ (0.9) $ 79.4 $ 91.0 $ — $ 1.2 $ 92.2 Cost of CDMO $ 75.6 $ — $ (1.6) $ 74.0 $ 78.8 $ — $ 1.0 $ 79.8 Income (loss) from operations $ 6.4 $ — $ 0.5 $ 6.9 $ (72.0) $ — $ (4.3) $ (76.3) Net income (loss) $ (3.7) $ (1.4) $ 0.5 $ (4.6) $ (56.4) $ 7.8 $ (4.3) $ (52.9) Net income (loss) per common share: Basic $ (0.07) $ (0.03) $ 0.01 $ (0.09) $ (1.13) $ 0.16 $ (0.09) $ (1.06) Diluted $ (0.07) $ (0.03) $ 0.01 $ (0.09) $ (1.13) $ 0.16 $ (0.09) $ (1.06) The following table presents the impact of the financial statement adjustments on the Company's previously reported Quarterly Condensed Consolidated Statements of Operations for the three months ended March 31, 2023 and June 30, 2023: Three Months Ended Three Months Ended March 31, 2023 June 30, 2023 Previously Reported Tax Adjustments Other Adjustments As Revised Previously Reported Tax Adjustments Other Adjustments As Revised Total revenues $ 165.1 $ — $ (0.8) $ 164.3 $ 337.9 $ — $ — $ 337.9 Cost of product sales $ 102.9 $ — $ (1.7) $ 101.2 $ 134.9 $ — $ — $ 134.9 Cost of CDMO $ 52.2 $ — $ (0.5) $ 51.7 $ 55.7 $ — $ — $ 55.7 Income (loss) from operations $ (148.1) $ — $ 0.5 $ (147.6) $ (292.9) $ — $ — $ (292.9) Net income (loss) $ (183.0) $ (3.7) $ 0.5 $ (186.2) $ (261.3) $ (0.1) $ — $ (261.4) Net income (loss) per common share: Basic $ (3.65) $ (0.07) $ 0.01 $ (3.71) $ (5.15) $ (0.01) $ — $ (5.16) Diluted $ (3.65) $ (0.07) $ 0.01 $ (3.71) $ (5.15) $ (0.01) $ — $ (5.16)

Nature of the business and or_2

Nature of the business and organization (Details)	9 Months Ended
	Sep. 30, 2023 category segment product Category
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of categories of public health threats | category	4
Number of revenue generating products | product	12
Number of product and service categories | Category	4
Number of operating segments	2
Number of reportable segments	2

Summary of significant accoun_3

Summary of significant accounting policies (Details) - USD ($) $ in Millions	May 15, 2023	Sep. 30, 2023	Dec. 31, 2022	Aug. 07, 2020
Debt Instrument [Line Items]
Long-term debt		$ 866.3	$ 1,413.8
Term Loan Facility | Amended Credit Agreement
Debt Instrument [Line Items]
Debt instrument, covenant, consideration threshold	$ 75
Outstanding credit facility		413.3
Line of Credit
Debt Instrument [Line Items]
Long-term debt		211.2	598
Term Loan | Revolving Credit Facility
Debt Instrument [Line Items]
Long-term debt		202.1	362.8
Senior Notes | Senior Unsecured Notes Due August 2028
Debt Instrument [Line Items]
Long-term debt		$ 450	$ 450	$ 450
Stated percentage		3.875%	3.875%	3.875%

Divestiture (Details)

Divestiture (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	May 15, 2023
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gain (loss) on sale of business	$ (0.7)	$ 0	$ 74.2	$ 0
Transaction costs	4		4
Other income (expense), net	(23.8)	$ (21.9)	5.9	$ (42.9)
Disposal Group, Disposed of by Sale, Not Discontinued Operations | Travel Health Business
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash purchase price for sale of business					$ 270
Other income (expense), net	$ 1.2		$ 2.2
Disposal Group, Disposed of by Sale, Not Discontinued Operations | Travel Health Business | Development-Based Milestones
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Milestone payments receivable					80
Disposal Group, Disposed of by Sale, Not Discontinued Operations | Travel Health Business | Sales-Based Milestones
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Milestone payments receivable					$ 30

Long-lived asset impairment a_3

Long-lived asset impairment and restructuring charges - Narrative (Details) $ in Millions	1 Months Ended		3 Months Ended				9 Months Ended
	Aug. 31, 2023 employee	Jan. 31, 2023 employee	Sep. 30, 2023 USD ($)	Jun. 30, 2023 USD ($)	Mar. 31, 2023 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)
Restructuring Cost and Reserve [Line Items]
Impairment of long-lived assets			$ 0			$ 0	$ 306.7	$ 0
Restructuring costs			20.3				29.9
January 2023 Restructuring Plan
Restructuring Cost and Reserve [Line Items]
Workforce reduction | employee		125
Restructuring costs			(0.2)	$ (0.1)	$ 9.7		$ 9.4
August 2023 Restructuring Plan
Restructuring Cost and Reserve [Line Items]
Workforce reduction | employee	400
Restructuring costs			$ 20.5	$ 0	$ 0

Long-lived asset impairment a_4

Long-lived asset impairment and restructuring charges - Schedule of Impairment of Long-Lived Assets Held and Used by Asset (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Impaired Long-Lived Assets Held and Used [Line Items]
Impairment of long-lived assets	$ 0	$ 0	$ 306.7	$ 0
Buildings, building improvements and leasehold improvements
Impaired Long-Lived Assets Held and Used [Line Items]
Impairment of long-lived assets	0		81.5
Furniture and equipment
Impaired Long-Lived Assets Held and Used [Line Items]
Impairment of long-lived assets	0		117.5
Software
Impaired Long-Lived Assets Held and Used [Line Items]
Impairment of long-lived assets	0		0.3
Construction-in-progress
Impaired Long-Lived Assets Held and Used [Line Items]
Impairment of long-lived assets	$ 0		$ 107.4

Long-lived asset impairment a_5

Long-lived asset impairment and restructuring charges - Schedule Restructuring and Related Costs (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Restructuring Cost and Reserve [Line Items]
Restructuring costs	$ 20.3		$ 29.9
R&D
Restructuring Cost and Reserve [Line Items]
Restructuring costs	0.9		3.4
Employee transition
Restructuring Cost and Reserve [Line Items]
Restructuring costs	0.3		0.6
Severance payments
Restructuring Cost and Reserve [Line Items]
Restructuring costs	17.9		26.6
Employee benefits
Restructuring Cost and Reserve [Line Items]
Restructuring costs	2.1		2.7
Products
Restructuring Cost and Reserve [Line Items]
Restructuring costs	5	$ 0	7	$ 0
Services
Restructuring Cost and Reserve [Line Items]
Restructuring costs	8.1	$ 0	8.1	$ 0
Total restructuring costs by segment
Restructuring Cost and Reserve [Line Items]
Restructuring costs	13.1		15.1
Total restructuring costs by segment | Products
Restructuring Cost and Reserve [Line Items]
Restructuring costs	5		7
Total restructuring costs by segment | Services
Restructuring Cost and Reserve [Line Items]
Restructuring costs	8.1		8.1
Corporate
Restructuring Cost and Reserve [Line Items]
Restructuring costs	$ 6.3		$ 11.4

Long-lived asset impairment a_6

Long-lived asset impairment and restructuring charges - Schedule of Restructuring Reserve by Type of Cost (Details) - USD ($) $ in Millions	3 Months Ended			9 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2023
Restructuring Reserve [Roll Forward]
Restructuring costs	$ 20.3			$ 29.9
January 2023 Restructuring Plan
Restructuring Reserve [Roll Forward]
Beginning balance	3.6	$ 7.4	$ 0	0
Restructuring costs	(0.2)	(0.1)	9.7	9.4
Cash payments	(1.1)	(3.7)	(2.3)
Ending balance	2.3	3.6	7.4	2.3
August 2023 Restructuring Plan
Restructuring Reserve [Roll Forward]
Beginning balance	0	0	0	0
Restructuring costs	20.5	0	0
Cash payments	(1.9)	0	0
Ending balance	18.6	0	0	18.6
Employee transition
Restructuring Reserve [Roll Forward]
Restructuring costs	0.3			0.6
Employee transition | January 2023 Restructuring Plan
Restructuring Reserve [Roll Forward]
Beginning balance	0.1	0.1	0	0
Restructuring costs	0	0	0.3
Cash payments	0	0	(0.2)
Ending balance	0.1	0.1	0.1	0.1
Employee transition | August 2023 Restructuring Plan
Restructuring Reserve [Roll Forward]
Beginning balance	0	0	0	0
Restructuring costs	0.3	0	0
Cash payments	(0.2)	0	0
Ending balance	0.1	0	0	0.1
Severance payments
Restructuring Reserve [Roll Forward]
Restructuring costs	17.9			26.6
Severance payments | January 2023 Restructuring Plan
Restructuring Reserve [Roll Forward]
Beginning balance	3.2	6.7	0	0
Restructuring costs	0	0.1	8.7
Cash payments	(1.1)	(3.6)	(2)
Ending balance	2.1	3.2	6.7	2.1
Severance payments | August 2023 Restructuring Plan
Restructuring Reserve [Roll Forward]
Beginning balance	0	0	0	0
Restructuring costs	17.9	0	0
Cash payments	(1.7)	0	0
Ending balance	16.2	0	0	16.2
Employee benefits
Restructuring Reserve [Roll Forward]
Restructuring costs	2.1			2.7
Employee benefits | January 2023 Restructuring Plan
Restructuring Reserve [Roll Forward]
Beginning balance	0.3	0.6	0	0
Restructuring costs	(0.2)	(0.2)	0.7
Cash payments	0	(0.1)	(0.1)
Ending balance	0.1	0.3	0.6	0.1
Employee benefits | August 2023 Restructuring Plan
Restructuring Reserve [Roll Forward]
Beginning balance	0	0	0	0
Restructuring costs	2.3	0	0
Cash payments	0	0	0
Ending balance	$ 2.3	$ 0	$ 0	$ 2.3

Inventories, net - Schedule of

Inventories, net - Schedule of Inventory (Details) - USD ($) $ in Millions	Sep. 30, 2023	Dec. 31, 2022	Sep. 30, 2022
Inventory Disclosure [Abstract]
Raw materials and supplies	$ 142.3	$ 142.3
Work-in-process	146.3	116.2
Finished goods	65.5	92.2
Total inventories, net	$ 354.1	$ 350.7	$ 528.2

Property, plant and equipment_3

Property, plant and equipment, net - Schedule of Property, Plant, and Equipment (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Property, plant and equipment, gross	$ 796.3		$ 796.3		$ 1,201.4
Less: Accumulated depreciation & amortization	(400.9)		(400.9)		(383.8)
Total property, plant and equipment, net	395.4	$ 806.8	395.4	$ 806.8	817.6
Impairment of long-lived assets	0	$ 0	306.7	$ 0
Land and improvements
Property, Plant and Equipment [Abstract]
Property, plant and equipment, gross	30		30		54.9
Buildings, building improvements and leasehold improvements
Property, Plant and Equipment [Abstract]
Property, plant and equipment, gross	228.9		228.9		327.9
Furniture and equipment
Property, Plant and Equipment [Abstract]
Property, plant and equipment, gross	428.5		428.5		567.5
Software
Property, Plant and Equipment [Abstract]
Property, plant and equipment, gross	64		64		65.6
Construction-in-progress
Property, Plant and Equipment [Abstract]
Property, plant and equipment, gross	$ 44.9		$ 44.9		$ 185.5

Property, plant and equipment -

Property, plant and equipment - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Cost of goods and services sold	$ 176.8	$ 147.2	$ 520.3	$ 472.6
Jansen Pharmaceuticals, Inc. | Services
Property, Plant and Equipment [Line Items]
Cost of goods and services sold					$ 12.7

Intangible assets and goodwil_2

Intangible assets and goodwill - Schedule of Finite-Lived Intangible Assets (Details) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 889.5	$ 1,016.2
Accumulated Amortization	306.7	287.4
Net Carrying Amount	582.8	728.8
Chimerix
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets acquired	$ 6.3
BARDA | Ebanga
Finite-Lived Intangible Assets [Line Items]
Term of contract	10 years
Disposal Group, Disposed of by Sale, Not Discontinued Operations | Travel Health Business
Finite-Lived Intangible Assets [Line Items]
Intangible assets disposed of in sale	$ 102.9
Products
Finite-Lived Intangible Assets [Line Items]
Weighted Average Useful Life in Years	13 years 6 months
Gross Carrying Amount	$ 855.4	982.1
Accumulated Amortization	272.6	253.3
Net Carrying Amount	$ 582.8	728.8
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Weighted Average Useful Life in Years	0 years
Gross Carrying Amount	$ 28.6	28.6
Accumulated Amortization	28.6	28.6
Net Carrying Amount	$ 0	0
CDMO
Finite-Lived Intangible Assets [Line Items]
Weighted Average Useful Life in Years	0 years
Gross Carrying Amount	$ 5.5	5.5
Accumulated Amortization	5.5	5.5
Net Carrying Amount	$ 0	$ 0

Intangible assets and goodwil_3

Intangible assets and goodwill - Schedule of Finite-lived Intangible Assets Amortization Expense (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense	$ 16.3	$ 14	$ 49.4	$ 42

Intangible assets and goodwil_4

Intangible assets and goodwill - Schedule of Goodwill (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Goodwill [Roll Forward]
Goodwill, beginning balance			$ 218,200,000
Goodwill impairment	$ (218,200,000)	$ 0	(218,200,000)	$ 0
Goodwill, ending balance	0	$ 224,900,000	0	$ 224,900,000
Products
Goodwill [Roll Forward]
Goodwill, beginning balance			218,200,000
Goodwill impairment	(218,200,000)
Goodwill, ending balance	0		0
Goodwill, gross	259,900,000		259,900,000		$ 259,900,000
Goodwill, impaired, accumulated impairment loss	259,900,000		259,900,000		259,900,000
Services
Goodwill [Roll Forward]
Goodwill, beginning balance			0
Goodwill impairment			0
Goodwill, ending balance	0		0
Goodwill, gross	6,700,000		6,700,000		6,700,000
Goodwill, impaired, accumulated impairment loss	$ 6,700,000		$ 6,700,000		$ 6,700,000

Intangible assets and goodwil_5

Intangible assets and goodwill - Narrative (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Finite-Lived Intangible Assets [Line Items]
Goodwill impairment	$ 218,200,000	$ 0	$ 218,200,000	$ 0
Goodwill	0	$ 224,900,000	0	$ 224,900,000	$ 218,200,000
Products
Finite-Lived Intangible Assets [Line Items]
Goodwill impairment	218,200,000
Goodwill	$ 0		$ 0		$ 218,200,000

Fair value measurements - Sched

Fair value measurements - Schedule of Fair Value Hierarchy of Assets and Liabilities (Details) - USD ($) $ in Millions	Sep. 30, 2023	Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative instruments	$ 0	$ 8.5
Total	37.2	500
Contingent consideration	5.4	8
Total	5.4	8
Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative instruments	0	0
Total	37.2	320.8
Contingent consideration	0	0
Total	0	0
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative instruments	0	8.5
Total	0	179.2
Contingent consideration	0	0
Total	0	0
Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative instruments	0	0
Total	0	0
Contingent consideration	5.4	8
Total	5.4	8
Money market accounts
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	37.2	320.8
Money market accounts | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	37.2	320.8
Money market accounts | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0	0
Money market accounts | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0	0
Time deposits
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0	170.7
Time deposits | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0	0
Time deposits | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0	170.7
Time deposits | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	$ 0	$ 0

Fair value measurements - Sch_2

Fair value measurements - Schedule of Contingent Consideration Roll Forward (Details) - Level 3 - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023
Unobservable Input Reconciliation [Roll Forward]
Balance, beginning of period	$ 7.4	$ 7.6	$ 8
Change in fair value	(1.1)	0.4	0.3
Settlements	(0.9)	(0.6)	(0.7)
Balance, end of period	$ 5.4	$ 7.4	$ 7.6

Fair value measurements - Narra

Fair value measurements - Narrative (Details) - USD ($) $ in Millions	Sep. 30, 2023	Dec. 31, 2022	Aug. 07, 2020
Debt Instrument [Line Items]
Business combination, contingent consideration, liability, current	$ 2.1	$ 3.4
Senior Unsecured Notes Due August 2028 | Senior Notes
Debt Instrument [Line Items]
Stated percentage	3.875%	3.875%	3.875%
Long-term debt, fair value	$ 190.1	$ 225.1

Fair value measurements - Sch_3

Fair value measurements - Schedule of Fair Value Level 3 of Significant Unobservable Inputs (Details) - Level 3 $ in Millions	Sep. 30, 2023 USD ($)	Jun. 30, 2023 USD ($)	Mar. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair value, measurement with unobservable inputs reconciliation, recurring basis, liability value	$ 5.4	$ 7.4	$ 7.6	$ 8
Fair Value, Recurring
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair value, measurement with unobservable inputs reconciliation, recurring basis, liability value	$ 5.4
Fair Value, Recurring | Discount rate | Discounted cash flow
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Business combination, contingent consideration, liability, measurement input	0.104
Fair Value, Recurring | Probability of payment | Discounted cash flow | Minimum
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Business combination, contingent consideration, liability, measurement input	0
Fair Value, Recurring | Probability of payment | Discounted cash flow | Maximum
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Business combination, contingent consideration, liability, measurement input	0.75

Derivative instruments and he_3

Derivative instruments and hedging activities - Narrative (Details) - Interest Rate Swaps - Designated as Hedging Instrument - USD ($)	Sep. 30, 2023	Jun. 30, 2023
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, notional amount		$ 350,000,000
AOCI before tax, attributable to parent	$ 500,000

Derivative instruments and he_4

Derivative instruments and hedging activities - Schedule of Derivative Instruments in Statement of Financial Position, Fair Value (Details) - USD ($) $ in Millions	Sep. 30, 2023	Dec. 31, 2022
Other Current Assets | Interest Rate Swaps | Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Derivative asset, subject to master netting arrangement, before offset	$ 0	$ 8.5

Derivative instruments and he_5

Derivative instruments and hedging activities - Schedule of Derivative Instruments, Gain (Loss) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Interest Rate Swaps | Cash Flow Hedging | Interest expense
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Other comprehensive income (loss), cash flow hedge, gain (loss), reclassification, before tax	$ 3.1	$ 0.4	$ 8.4	$ (1.9)

Debt - Schedule of Debt (Detail

Debt - Schedule of Debt (Details) - USD ($) $ in Millions	Sep. 30, 2023	Dec. 31, 2022	Sep. 30, 2022	Aug. 07, 2020
Debt Instrument [Line Items]
Total debt	$ 866.3	$ 1,413.8
Less: Unamortized debt issuance costs	(4.5)	(8)
Less: Current portion of long-term debt, net	(413.6)	(957.3)
Non-current portion of debt, net	448.2	448.5	$ 1,032.1
Other
Debt Instrument [Line Items]
Total debt	3	3
Line of Credit
Debt Instrument [Line Items]
Total debt	$ 211.2	$ 598
Senior Notes | Senior Unsecured Notes Due August 2028
Debt Instrument [Line Items]
Stated percentage	3.875%	3.875%		3.875%
Total debt	$ 450	$ 450		$ 450
Revolving Credit Facility | Term Loan
Debt Instrument [Line Items]
Total debt	$ 202.1	$ 362.8

Debt - Narrative (Details)

Debt - Narrative (Details) $ in Millions	May 15, 2023 USD ($)	Aug. 07, 2020 USD ($)	Sep. 30, 2023 USD ($)	May 14, 2023 USD ($)	Dec. 31, 2022 USD ($)
Debt Instrument [Line Items]
Debt issuance costs, current, net			$ 9.4		$ 1.3
Long-term debt			866.3		1,413.8
Disposal Group, Disposed of by Sale, Not Discontinued Operations
Debt Instrument [Line Items]
Cash	$ 217.2
Disposal Group, Disposed of by Sale, Not Discontinued Operations | Travel Health Business
Debt Instrument [Line Items]
Cash purchase price for sale of business	270
Revolving Credit Facility
Debt Instrument [Line Items]
Repayments of long-term debt	342.8
Line of Credit
Debt Instrument [Line Items]
Long-term debt			211.2		598
Term Loan
Debt Instrument [Line Items]
Repayments of long-term debt	$ 144.4
Term Loan | Revolving Credit Facility
Debt Instrument [Line Items]
Long-term debt			$ 202.1		$ 362.8
Senior Unsecured Notes Due August 2028 | Prior to August 15, 2023
Debt Instrument [Line Items]
Debt instrument, redemption price, percentage		100%
Senior Unsecured Notes Due August 2028 | Upon the occurrence of a change in control | Maximum
Debt Instrument [Line Items]
Debt instrument, redemption price, percentage		101%
Senior Unsecured Notes Due August 2028 | Senior Notes
Debt Instrument [Line Items]
Stated percentage		3.875%	3.875%		3.875%
Long-term debt		$ 450	$ 450		$ 450
Amended Credit Agreement | Federal Funds Rate
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate	0.50%
Amended Credit Agreement | Secured Overnight Financing Rate (SOFR)
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate	1%
Amended Credit Agreement | Base Rate
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate	5%
Amended Credit Agreement | Until March 31, 2024 | SOFR, EURIBOR, or CDOR
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate	6%
Amended Credit Agreement | Revolving Credit Facility
Debt Instrument [Line Items]
Current borrowing capacity	$ 300			$ 600
Required quarterly principal payments	3.9
Amended Credit Agreement | Term Loan Facility
Debt Instrument [Line Items]
Debt instrument, covenant, consideration threshold	$ 75
Amended Credit Agreement | Maximum | Fiscal Quarters Ending After March 31, 2024 | SOFR, EURIBOR, or CDOR
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate	4%
Amended Credit Agreement | Maximum | Fiscal Quarters Ending After March 31, 2024 | Base Rate
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate	3%
Amended Credit Agreement | Maximum | Revolving Credit Facility
Debt Instrument [Line Items]
Line of credit facility, unused capacity, commitment fee percentage	0.40%
Amended Credit Agreement | Minimum | Fiscal Quarters Ending After March 31, 2024 | SOFR, EURIBOR, or CDOR
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate	2.75%
Amended Credit Agreement | Minimum | Fiscal Quarters Ending After March 31, 2024 | Base Rate
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate	1.75%
Amended Credit Agreement | Minimum | Revolving Credit Facility
Debt Instrument [Line Items]
Line of credit facility, unused capacity, commitment fee percentage	0.15%
Amended Credit Agreement | Line of Credit
Debt Instrument [Line Items]
Debt instrument, covenant, leverage ratio, maximum	4.50
Amended Credit Agreement | Line of Credit | Fiscal Quarters Ending in 2024
Debt Instrument [Line Items]
Debt instrument, covenant, interest coverage ratio, minimum	2.25
Amended Credit Agreement | Line of Credit | Fiscal Quarters Ending After 2024
Debt Instrument [Line Items]
Debt instrument, covenant, interest coverage ratio, minimum	2.50

Stock-based compensation and _3

Stock-based compensation and stockholders' equity - Narrative (Details) - USD ($) $ / shares in Units, $ in Millions		3 Months Ended				4 Months Ended	9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2023	Sep. 30, 2023	Sep. 30, 2022	Nov. 11, 2022	Sep. 28, 2023	Nov. 11, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options granted (in shares)							800,000
Nonvested options forfeited (in shares)							900,000
Stock repurchase program, authorized amount											$ 250
Stock repurchased during period, value				$ 23.3	$ 52.2
Treasury Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock repurchased during period, value				$ 23.3	$ 52.2			$ 75.5	$ 187.9
Stock repurchased during period, shares (in shares)			0	700,000	1,100,000			1,800,000	4,400,000
2023 Equity Inducement Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, capital shares reserved for future issuance (in shares)										5,000,000
Number of shares issued (in shares)	0
At-The-Market Offering
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Sale of stock, aggregate offering amount, maximum	$ 150	$ 150				$ 150	$ 150
Sale of stock, number of shares issued in transaction (in shares)		0				1,100,000
Sale of stock, consideration received on transaction, gross						$ 9.1
Sale of stock, price per share (in dollars per share)	$ 8.22	$ 8.22				$ 8.22	$ 8.22
Sale of stock, amount remaining available for sale of shares	$ 140.9	$ 140.9				$ 140.9	$ 140.9
Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Equity instruments other than options granted (in shares)							1,600,000
Equity instruments other than options, forfeited in period (in shares)							700,000
Restricted Stock Units | Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting rights, percentage							33.33%
Restricted Stock Units | Tranche Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting rights, percentage							33.33%
Restricted Stock Units | Tranche Three
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting rights, percentage							33.33%
Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Equity instruments other than options granted (in shares)							500,000
Target payout percentage	100%	100%				100%	100%
Maximum payout percentage	200%	200%				200%	200%
Award vesting period							3 years
Equity instruments other than options, forfeited in period (in shares)							300,000
Stock Options | Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting rights, percentage							33.33%
Stock Options | Tranche Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting rights, percentage							33.33%
Stock Options | Tranche Three
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting rights, percentage							33.33%

Stock-based compensation and _4

Stock-based compensation and stockholders' equity - Schedule of Stock-based Compensation Expense (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ 4	$ 11.2	$ 19.1	$ 33.4
R&D
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	0.6	1.3	1.7	3.9
Selling, general and administrative
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	2.2	7.7	13	22.7
Products (2) | Cost of product sales
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	1	1.8	3.6	5.4
CDMO | Cost of product sales
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ 0.2	$ 0.4	$ 0.8	$ 1.4

Stock-based compensation and _5

Stock-based compensation and stockholders' equity - Schedule of Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Millions	3 Months Ended						9 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2023	Sep. 30, 2022
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	$ 957.7	$ 1,204.1	$ 1,387.7	$ 1,508.3	$ 1,566.9	$ 1,611.5	$ 1,387.7	$ 1,611.5
Other comprehensive income (loss) before reclassifications	2.1	3.8	(4.5)	1.3	2.3	5.4
Amounts reclassified from accumulated other comprehensive income (loss)	(3.1)	(6.4)	2.4	(0.4)	0.9	1.4
Total other comprehensive income (loss), net of tax	(1)	(2.6)	(2.1)	0.9	3.2	6.8	(5.7)	10.9
Ending balance	697.2	957.7	1,204.1	1,433	1,508.3	1,566.9	697.2	1,433
Total
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	(1.6)	1	3.1	(6.1)	(9.3)	(16.1)	3.1	(16.1)
Total other comprehensive income (loss), net of tax	(1)	(2.6)	(2.1)	0.9	3.2	6.8
Ending balance	(2.6)	(1.6)	1	(5.2)	(6.1)	(9.3)	(2.6)	(5.2)
Defined Benefit Pension Plan
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	0	3.5	3.5	(4)	(4)	(4)	3.5	(4)
Other comprehensive income (loss) before reclassifications	0	0	0	0	0	0
Amounts reclassified from accumulated other comprehensive income (loss)	0	(3.5)	0	0	0	0
Total other comprehensive income (loss), net of tax	0	(3.5)	0	0	0	0	(3.5)	0
Ending balance	0	0	3.5	(4)	(4)	(4)	0	(4)
Derivative Instruments
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	2.5	4.2	6.2	4.6	1.8	(4.5)	6.2	(4.5)
Other comprehensive income (loss) before reclassifications	0.9	1.2	(4.4)	2.6	1.9	4.9
Amounts reclassified from accumulated other comprehensive income (loss)	(3.1)	(2.9)	2.4	(0.4)	0.9	1.4
Total other comprehensive income (loss), net of tax	(2.2)	(1.7)	(2)	2.2	2.8	6.3	(5.9)	11.3
Ending balance	0.3	2.5	4.2	6.8	4.6	1.8	0.3	6.8
Foreign Currency Translation Adjustments
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	(4.1)	(6.7)	(6.6)	(6.7)	(7.1)	(7.6)	(6.6)	(7.6)
Other comprehensive income (loss) before reclassifications	1.2	2.6	(0.1)	(1.3)	0.4	0.5
Amounts reclassified from accumulated other comprehensive income (loss)	0	0	0	0	0	0
Total other comprehensive income (loss), net of tax	1.2	2.6	(0.1)	(1.3)	0.4	0.5	3.7	(0.4)
Ending balance	$ (2.9)	$ (4.1)	$ (6.7)	$ (8)	$ (6.7)	$ (7.1)	$ (2.9)	$ (8)

Stock-based compensation and _6

Stock-based compensation and stockholders' equity - Schedule of Comprehensive Income (Loss) (Details) - USD ($) $ in Millions	3 Months Ended						9 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2023	Sep. 30, 2022
Accumulated Other Comprehensive Income (Loss) [Line Items]
Pretax	$ (2.2)			$ 3.1			$ (9.2)	$ 17.5
Tax Expense	1.2			(2.2)			3.5	(6.6)
Total other comprehensive income (loss), net of tax	(1)	$ (2.6)	$ (2.1)	0.9	$ 3.2	$ 6.8	(5.7)	10.9
Defined Benefit Pension Plan
Accumulated Other Comprehensive Income (Loss) [Line Items]
Pretax	0			0			(4.1)	0
Tax Expense	0			0			0.6	0
Total other comprehensive income (loss), net of tax	0	(3.5)	0	0	0	0	(3.5)	0
Derivative Instruments
Accumulated Other Comprehensive Income (Loss) [Line Items]
Pretax	(3.1)			3			(8)	15.4
Tax Expense	0.9			(0.8)			2.1	(4.1)
Total other comprehensive income (loss), net of tax	(2.2)	(1.7)	(2)	2.2	2.8	6.3	(5.9)	11.3
Foreign Currency Translation Adjustments
Accumulated Other Comprehensive Income (Loss) [Line Items]
Pretax	0.9			0.1			2.9	2.1
Tax Expense	0.3			(1.4)			0.8	(2.5)
Total other comprehensive income (loss), net of tax	$ 1.2	$ 2.6	$ (0.1)	$ (1.3)	$ 0.4	$ 0.5	$ 3.7	$ (0.4)

Loss per common share - Schedul

Loss per common share - Schedule of Basic and Diluted Net Loss per Share (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended						9 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2023	Sep. 30, 2022
Numerator:
Net loss	$ (263.4)	$ (261.4)	$ (186.2)	$ (87.1)	$ (52.9)	$ (4.6)	$ (711)	$ (144.6)
Denominator:
Weighted-average number of shares outstanding-basic (in shares)	51.8			49.9			50.9	50.2
Weighted-average number of shares outstanding-diluted (in shares)	51.8			49.9			50.9	50.2
Loss per common share - basic (in dollars per share)	$ (5.08)	$ (5.16)	$ (3.71)	$ (1.75)	$ (1.06)	$ (0.09)	$ (13.97)	$ (2.88)
Loss per common share - diluted (in dollars per share)	$ (5.08)	$ (5.16)	$ (3.71)	$ (1.75)	$ (1.06)	$ (0.09)	$ (13.97)	$ (2.88)
Anti-dilutive securities (in shares)	4			3.3			3.6	2.6

Revenue recognition - Schedule

Revenue recognition - Schedule of Disaggregation of Revenue (Details) - USD ($) $ in Millions	3 Months Ended						9 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2023	Sep. 30, 2022
Disaggregation of Revenue [Line Items]
Total revenues	$ 270.5	$ 337.9	$ 164.3	$ 239.9	$ 242.6	$ 304.8	$ 772.7	$ 787.3
USG
Disaggregation of Revenue [Line Items]
Total revenues	108.1			49.8			294.2	286.7
Non-USG
Disaggregation of Revenue [Line Items]
Total revenues	162.4			190.1			478.5	500.6
Product sales, net
Disaggregation of Revenue [Line Items]
Revenue	249.8			186.2			695.4	660.5
Product sales, net | USG
Disaggregation of Revenue [Line Items]
Revenue	103			33.4			279.6	255
Product sales, net | Non-USG
Disaggregation of Revenue [Line Items]
Revenue	146.8			152.8			415.8	405.5
CDMO
Disaggregation of Revenue [Line Items]
Total CDMO revenues	14.2			36.3			57.7	92.5
CDMO | USG
Disaggregation of Revenue [Line Items]
Total CDMO revenues	0			0			0	0
CDMO | Non-USG
Disaggregation of Revenue [Line Items]
Total CDMO revenues	14.2			36.3			57.7	92.5
Services
Disaggregation of Revenue [Line Items]
Revenue	13.2			36.1			52.2	87.8
Services | USG
Disaggregation of Revenue [Line Items]
Revenue	0			0			0	0
Services | Non-USG
Disaggregation of Revenue [Line Items]
Revenue	13.2			36.1			52.2	87.8
Leases
Disaggregation of Revenue [Line Items]
Leases	1			0.2			5.5	4.7
Leases | USG
Disaggregation of Revenue [Line Items]
Leases	0			0			0	0
Leases | Non-USG
Disaggregation of Revenue [Line Items]
Leases	1			0.2			5.5	4.7
Contracts and grants
Disaggregation of Revenue [Line Items]
Revenue	6.5			17.4			19.6	34.3
Contracts and grants | USG
Disaggregation of Revenue [Line Items]
Revenue	5.1			16.4			14.6	31.7
Contracts and grants | Non-USG
Disaggregation of Revenue [Line Items]
Revenue	$ 1.4			$ 1			$ 5	$ 2.6

Revenue recognition - Narrative

Revenue recognition - Narrative (Details) - USD ($) $ in Millions	3 Months Ended
	Dec. 31, 2022	Sep. 30, 2023	Sep. 30, 2022
Disaggregation of Revenue [Line Items]
Revenue, remaining performance obligation, amount		$ 408.6
Contract with customer, asset, noncurrent	$ 34.8	38.4
Current portion of contract liabilities	26.4	22.9
Other assets	191.3	194.1	$ 40.8
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-10-01
Disaggregation of Revenue [Line Items]
Revenue, remaining performance obligation, amount		$ 400.3
Revenue, remaining performance obligation, expected timing of satisfaction, period		24 months
Jansen Pharmaceuticals, Inc.
Disaggregation of Revenue [Line Items]
Increase in other assets	$ 152.7
Other assets		$ 153.8
Non-cancelable orders		$ 5
Leases
Disaggregation of Revenue [Line Items]
Lessee, operating lease, remaining lease term		5 years 3 months 18 days
Lessor, operating lease, payment to be received, remainder of fiscal year		$ 0.2
Lessor, operating lease, payment to be received, year one		0.9
Lessor, operating lease, payment to be received, year two		0.9
Lessor, operating lease, payment to be received, year three		0.9
Lessor, operating lease, payment to be received, year four		0.9
Lessor, operating lease, payment to be received, after year four		$ 0.9

Revenue recognition - Schedul_2

Revenue recognition - Schedule of Rollforward of Contract Liabilities (Details) $ in Millions	9 Months Ended
	Sep. 30, 2023 USD ($)
Change in Contract With Customer, Liability [Roll Forward]
Beginning of period	$ 31.7
End of period	27.9
Revenue recognized in the period from amounts included in contract liability at the beginning of the period:	$ (7.3)

Revenue recognition - Schedul_3

Revenue recognition - Schedule of Accounts Receivable, Net (Details) - USD ($) $ in Millions	Sep. 30, 2023	Dec. 31, 2022	Sep. 30, 2022
Revenue from Contract with Customer [Abstract]
Billed	$ 156.6	$ 102.7
Unbilled	61	57.2
Allowance for expected credit losses	(1.1)	(0.7)
Accounts receivable, net	$ 216.5	$ 159.2	$ 189.2

Leases - Schedule of Components

Leases - Schedule of Components of Lease Expense (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Operating lease cost:
Amortization of right-of-use assets	$ 1.1	$ 1.4	$ 3.1	$ 4.2
Interest on lease liabilities	0.2	0.3	0.6	0.8
Total operating lease cost	$ 1.3	$ 1.7	$ 3.7	$ 5

Leases - Schedule of Leases Sup

Leases - Schedule of Leases Supplemental Balance Sheets (Details) - USD ($) $ in Millions	Sep. 30, 2023	Dec. 31, 2022
Operating Leases
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]	Other assets	Other assets
Operating lease right-of-use assets	$ 17.1	$ 19.4
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]	Other current liabilities	Other current liabilities
Operating lease liabilities, current portion	$ 3.5	$ 5.8
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]	Other liabilities	Other liabilities
Operating lease liabilities	$ 14.6	$ 14.8
Total operating lease liabilities	$ 18.1	$ 20.6
Operating leases:
Weighted average remaining lease term (years)	6 years 3 months 18 days	5 years 10 months 24 days
Weighted average discount rate	5.20%	4.10%

Income taxes (Details)

Income taxes (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2023	Dec. 31, 2022
Income Taxes [Line Items]
Effective annual tax rate						4%
Discrete tax expense (benefit)	$ 1	$ (9)	$ 1	$ (7.3)
Forecast
Income Taxes [Line Items]
Effective annual tax rate					(5.00%)
Valuation allowance, deferred tax asset, increase, amount					$ 163.1

Segment information - Narrative

Segment information - Narrative (Details)	9 Months Ended
	Sep. 30, 2023 segment
Segment Reporting [Abstract]
Number of reportable segments	2
Number of operating segments	2

Segment information - Schedule

Segment information - Schedule of Reconciliation of Operating Profit (Loss) from Segments to Consolidated (Details) - USD ($) $ in Millions	3 Months Ended						9 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2023	Sep. 30, 2022
Revenues:
Total revenues	$ 270.5	$ 337.9	$ 164.3	$ 239.9	$ 242.6	$ 304.8	$ 772.7	$ 787.3
Less: Cost of sales:
Cost of goods and services sold	176.8			147.2			520.3	472.6
Consolidated gross margin	87.2			75.3			232.8	280.4
Products:
Changes in fair value of contingent consideration							(0.4)	2.4
Restructuring costs	20.3						29.9
Services:
Restructuring costs	20.3						29.9
Adjusted Gross Margin	99.2			75.9			249.4	282.8
Other reconciling items:
Adjustments to gross margin	(12)			(0.6)			(16.6)	(2.4)
Goodwill impairment	(218.2)			0			(218.2)	0
Impairment of long-lived assets	0			0			(306.7)	0
Research and development	(15.3)			(42.2)			(82)	(141.3)
Selling, general and administrative	(86)			(81.8)			(278.7)	(246.1)
Amortization of intangible assets	(16.3)			(14)			(49.4)	(42)
Interest expense	(19.7)			(8.5)			(66.2)	(24.5)
Gain on sale of business	(0.7)			0			74.2	0
Other, net	(3.4)			(13.4)			(2.1)	(18.4)
Loss before income taxes	(265.9)			(67.2)			(676.7)	(157.6)
Contracts and grants
Revenues:
Revenue	6.5			17.4			19.6	34.3
Products And Services Segments
Revenues:
Revenue	264			222.5			753.1	753
Products
Revenues:
Revenue	249.8			186.2			695.4	660.5
Less: Cost of sales:
Cost of goods and services sold	132.5			85.2			368.6	256.8
Consolidated gross margin	117.3			101			326.8	403.7
Products:
Changes in fair value of contingent consideration	(1.1)			0.6			(0.4)	2.4
Restructuring costs	5			0			7	0
Inventory step-up provision	0			0			1.9	0
Services:
Restructuring costs	5			0			7	0
Adjusted Gross Margin	121.2			101.6			335.3	406.1
Other reconciling items:
Goodwill impairment	(218.2)
Services
Revenues:
Revenue	14.2			36.3			57.7	92.5
Less: Cost of sales:
Cost of goods and services sold	44.3			62			151.7	215.8
Consolidated gross margin	(30.1)			(25.7)			(94)	(123.3)
Products:
Restructuring costs	8.1			0			8.1	0
Services:
Restructuring costs	8.1			0			8.1	0
Adjusted Gross Margin	$ (22)			$ (25.7)			(85.9)	$ (123.3)
Other reconciling items:
Goodwill impairment							$ 0

Segment information - Schedul_2

Segment information - Schedule of Segment Reporting Information, by Segment (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Depreciation:
Total	$ 11.7	$ 20.3	$ 46.1	$ 65.4
Other
Depreciation:
Total	0.9	3.3	3.5	5.7
Products | Operating Segments
Depreciation:
Total	7.4	11.5	22.9	25.6
Services | Operating Segments
Depreciation:
Total	$ 3.4	$ 5.5	$ 19.7	$ 34.1

Adjustments to quarterly fina_3

Adjustments to quarterly financial data - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Income tax provision (benefit)	$ (2.5)	$ 19.9	$ 34.3	$ (13)
Tax Adjustments
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Income tax provision (benefit)		$ 8.1		$ 1.7

Adjustments to quarterly fina_4

Adjustments to quarterly financial data - Balance Sheet (Details) - USD ($) $ / shares in Units, $ in Millions	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 87.8			$ 642.6	$ 240.9
Restricted cash				0	0.1
Accounts receivable, net	216.5			159.2	189.2
Inventories, net	354.1			350.7	528.2
Prepaid expenses and other current assets	62.4			57.9	139.9
Total current assets	720.8			1,210.4	1,098.3
Property, plant and equipment, net	395.4			817.6	806.8
Intangible assets, net	582.8			728.8	724.9
Goodwill	0			218.2	224.9
Other assets	194.1			191.3	40.8
Total assets	1,893.1			3,166.3	2,895.7
Current liabilities:
Contingent consideration payable	112.7			103.5	101
Accrued expenses	17			34.9	35.7
Accrued compensation	82.5			87.3	82.5
Debt, current portion	413.6			957.3	21.2
Other current liabilities	38.2			45.9	24
Total current liabilities	664			1,228.9	264.4
Non-current portion of debt, net	448.2			448.5	1,032.1
Deferred tax liability	52.4			59.7	113.9
Other liabilities	31.3			41.5	52.3
Total liabilities	1,195.9			1,778.6	1,462.7
Stockholders' equity:
Preferred stock, par value $0.001 per share; 15.0 shares authorized, no shares issued or outstanding	0			0	0
Common stock, $0.001 par value; 200.0 shares authorized, 55.7 shares issued; 50.1 shares outstanding	0.1			0.1	0.1
Treasury stock, at cost, 5.6 common shares	(227.7)			(227.7)	(227.7)
Additional paid-in capital	899.7			873.5	860.1
Accumulated other comprehensive income (loss), net	(2.6)			3.1	(5.2)
Retained earnings	27.7			738.7	805.7
Total stockholders’ equity	697.2	$ 957.7	$ 1,204.1	1,387.7	1,433	$ 1,508.3	$ 1,566.9	$ 1,611.5
Total liabilities and stockholders’ equity	$ 1,893.1			$ 3,166.3	$ 2,895.7
Preferred stock, par value (in dollars per share)	$ 0.001			$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	15,000,000			15,000,000	15,000,000
Preferred stock, shares issued (in shares)	0			0	0
Preferred stock, shares outstanding (in shares)	0			0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001	$ 0.001	$ 0.001	$ 0.001	$ 0.001	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	200,000,000			200,000,000	200,000,000
Common stock, shares issued (in shares)	57,400,000			55,700,000	55,500,000
Common stock, shares outstanding (in shares)	51,800,000			50,100,000	49,900,000
Treasury stock (in shares)	5,600,000			5,600,000	5,600,000
Previously Reported
Current assets:
Cash and cash equivalents				$ 642.6	$ 240.9
Restricted cash				0	0.1
Accounts receivable, net				158.4	191.3
Inventories, net				351.8	546.3
Prepaid expenses and other current assets				57.9	139.9
Total current assets				1,210.7	1,118.5
Property, plant and equipment, net				817.6	806.7
Intangible assets, net				728.8	722.7
Goodwill				218.2	224.9
Other assets				191.3	35.7
Total assets				3,166.6	2,908.5
Current liabilities:
Contingent consideration payable				103.5	103.8
Accrued expenses				34.9	35.9
Accrued compensation				88.3	82.5
Debt, current portion				957.3	21.2
Other current liabilities				45.9	25
Total current liabilities				1,229.9	268.4
Non-current portion of debt, net				448.5	1,032.1
Deferred tax liability				71.8	113.8
Other liabilities				33.4	44.9
Total liabilities				1,783.6	1,459.2
Stockholders' equity:
Preferred stock, par value $0.001 per share; 15.0 shares authorized, no shares issued or outstanding				0	0
Common stock, $0.001 par value; 200.0 shares authorized, 55.7 shares issued; 50.1 shares outstanding				0.1	0.1
Treasury stock, at cost, 5.6 common shares				(227.7)	(227.7)
Additional paid-in capital				873.5	860.1
Accumulated other comprehensive income (loss), net				3.1	(5.2)
Retained earnings				734	822
Total stockholders’ equity				1,383	1,449.3
Total liabilities and stockholders’ equity				3,166.6	2,908.5
Tax Adjustments
Current liabilities:
Other current liabilities				(0.3)	(0.7)
Total current liabilities				(0.3)	(0.7)
Deferred tax liability				(12.1)	0.1
Other liabilities				7.1	6.5
Total liabilities				(5.3)	5.9
Stockholders' equity:
Retained earnings				5.3	(5.9)
Total stockholders’ equity				5.3	(5.9)
Other Adjustments
Current assets:
Accounts receivable, net				0.8	(2.1)
Inventories, net				(1.1)	(18.1)
Total current assets				(0.3)	(20.2)
Property, plant and equipment, net					0.1
Intangible assets, net					2.2
Other assets					5.1
Total assets				(0.3)	(12.8)
Current liabilities:
Contingent consideration payable					(2.8)
Accrued expenses					(0.2)
Accrued compensation				(1)
Other current liabilities				0.3	(0.3)
Total current liabilities				(0.7)	(3.3)
Deferred tax liability				0	0
Other liabilities				1	0.9
Total liabilities				0.3	(2.4)
Stockholders' equity:
Retained earnings				(0.6)	(10.4)
Total stockholders’ equity				(0.6)	(10.4)
Total liabilities and stockholders’ equity				$ (0.3)	$ (12.8)

Adjustments to quarterly fina_5

Adjustments to quarterly financial data - Statement of Operation (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended						9 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2023	Sep. 30, 2022
Revenues:
Total revenues	$ 270.5	$ 337.9	$ 164.3	$ 239.9	$ 242.6	$ 304.8	$ 772.7	$ 787.3
Operating expenses:
Cost of goods and services sold	176.8			147.2			520.3	472.6
Research and development	15.3			42.2			82	141.3
Selling, general and administrative	86			81.8			278.7	246.1
Amortization of intangible assets	16.3			14			49.4	42
Total operating expenses	512.6			285.2			1,455.3	902
Loss from operations	(242.1)	(292.9)	(147.6)	(45.3)	(76.3)	6.9	(682.6)	(114.7)
Other income (expense):
Interest expense	(19.7)			(8.5)			(66.2)	(24.5)
Other, net	(3.4)			(13.4)			(2.1)	(18.4)
Total other income (expense), net	(23.8)			(21.9)			5.9	(42.9)
Loss before income taxes	(265.9)			(67.2)			(676.7)	(157.6)
Income tax provision (benefit)	(2.5)			19.9			34.3	(13)
Net loss	$ (263.4)	$ (261.4)	$ (186.2)	$ (87.1)	$ (52.9)	$ (4.6)	$ (711)	$ (144.6)
Net loss per common share
Basic (in dollars per share)	$ (5.08)	$ (5.16)	$ (3.71)	$ (1.75)	$ (1.06)	$ (0.09)	$ (13.97)	$ (2.88)
Diluted (in dollars per share)	$ (5.08)	$ (5.16)	$ (3.71)	$ (1.75)	$ (1.06)	$ (0.09)	$ (13.97)	$ (2.88)
Weighted average shares outstanding
Basic (in shares)	51.8			49.9			50.9	50.2
Diluted (in shares)	51.8			49.9			50.9	50.2
Product sales, net
Revenues:
Services	$ 249.8			$ 186.2			$ 695.4	$ 660.5
Operating expenses:
Cost of goods and services sold	132.5	$ 134.9	$ 101.2	85.2	$ 92.2	$ 79.4	368.6	256.8
CDMO
Revenues:
Total CDMO revenues	14.2			36.3			57.7	92.5
Operating expenses:
Cost of goods and services sold	44.3	55.7	51.7	62	79.8	74	151.7	215.8
Services
Revenues:
Services	13.2			36.1			52.2	87.8
Leases
Revenues:
Leases	1			0.2			5.5	4.7
Contracts and grants
Revenues:
Services	$ 6.5			17.4			$ 19.6	34.3
Previously Reported
Revenues:
Total revenues		337.9	165.1	240	242.7	307.5		790.2
Operating expenses:
Research and development				39.2				135.4
Selling, general and administrative				80.2				246.1
Amortization of intangible assets				14				42
Total operating expenses				282				897.8
Loss from operations		(292.9)	(148.1)	(42)	(72)	6.4		(107.6)
Other income (expense):
Interest expense				(8.5)				(24.5)
Other, net				(13.4)				(18.4)
Total other income (expense), net				(21.9)				(42.9)
Loss before income taxes				(63.9)				(150.5)
Income tax provision (benefit)				11.8				(14.7)
Net loss		$ (261.3)	$ (183)	$ (75.7)	$ (56.4)	$ (3.7)		$ (135.8)
Net loss per common share
Basic (in dollars per share)		$ (5.15)	$ (3.65)	$ (1.52)	$ (1.13)	$ (0.07)		$ (2.71)
Diluted (in dollars per share)		$ (5.15)	$ (3.65)	$ (1.52)	$ (1.13)	$ (0.07)		$ (2.71)
Weighted average shares outstanding
Basic (in shares)				49.9				50.2
Diluted (in shares)				49.9				50.2
Previously Reported | Product sales, net
Revenues:
Services				$ 186.2				$ 660.5
Operating expenses:
Cost of goods and services sold		$ 134.9	$ 102.9	85.5	$ 91	$ 80.3		256.8
Previously Reported | CDMO
Revenues:
Total CDMO revenues				36.4				95.4
Operating expenses:
Cost of goods and services sold		55.7	52.2	63.1	78.8	75.6		217.5
Previously Reported | Services
Revenues:
Services				36.2				90.7
Previously Reported | Leases
Revenues:
Leases				0.2				4.7
Previously Reported | Contracts and grants
Revenues:
Services				17.4				34.3
Tax Adjustments
Other income (expense):
Income tax provision (benefit)				8.1				1.7
Net loss		$ (0.1)	$ (3.7)	$ (8.1)	$ 7.8	$ (1.4)		$ (1.7)
Net loss per common share
Basic (in dollars per share)		$ (0.01)	$ (0.07)	$ (0.16)	$ 0.16	$ (0.03)		$ (0.03)
Diluted (in dollars per share)		$ (0.01)	$ (0.07)	$ (0.16)	$ 0.16	$ (0.03)		$ (0.03)
Other Adjustments
Revenues:
Total revenues			$ (0.8)	$ (0.1)	$ (0.1)	$ (2.7)		$ (2.9)
Operating expenses:
Research and development				3				5.9
Selling, general and administrative				1.6
Total operating expenses				3.2				4.2
Loss from operations			0.5	(3.3)	(4.3)	0.5		(7.1)
Other income (expense):
Loss before income taxes				(3.3)				(7.1)
Net loss			$ 0.5	$ (3.3)	$ (4.3)	$ 0.5		$ (7.1)
Net loss per common share
Basic (in dollars per share)			$ 0.01	$ (0.07)	$ (0.09)	$ 0.01		$ (0.14)
Diluted (in dollars per share)			$ 0.01	$ (0.07)	$ (0.09)	$ 0.01		$ (0.14)
Other Adjustments | Product sales, net
Operating expenses:
Cost of goods and services sold			$ (1.7)	$ (0.3)	$ 1.2	$ (0.9)
Other Adjustments | CDMO
Revenues:
Total CDMO revenues				(0.1)				$ (2.9)
Operating expenses:
Cost of goods and services sold			$ (0.5)	(1.1)	$ 1	$ (1.6)		(1.7)
Other Adjustments | Services
Revenues:
Services				$ (0.1)				$ (2.9)

Adjustments to quarterly fina_6

Adjustments to quarterly financial data - Statement of Cash Flow (Details) - USD ($) $ in Millions	3 Months Ended						9 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Operating Activities
Net loss	$ (263.4)	$ (261.4)	$ (186.2)	$ (87.1)	$ (52.9)	$ (4.6)	$ (711)	$ (144.6)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense							19.1	33.4
Depreciation and amortization							95.5	107.6
Change in fair value of contingent obligations, net							(0.4)	2.4
Amortization of deferred financing costs							15.6	3.1
Deferred income taxes							(3.7)	25.5
Other							8.9	13
Changes in operating assets and liabilities:
Accounts receivable							(58.5)	82.5
Inventories							(25)	(102.8)
Prepaid expenses and other assets							(18.3)	(34.3)
Accounts payable							17.7	(11.8)
Accrued expenses and other liabilities							(30.2)	(48.4)
Accrued compensation							(0.8)	(5.7)
Income taxes receivable and payable, net							(3.5)	(51)
Contract liabilities							1.8	4.2
Net cash used in operating activities							(238.4)	(126.9)
Investing Activities
Purchases of property, plant and equipment							(40.2)	(92.2)
Asset acquisitions							0	(243.7)
Net cash provided by (used in) investing activities							223.7	(335.9)
Financing Activities
Purchases of treasury stock							0	(81.9)
Proceeds from revolving credit facility							0	238
Principal payments on term loan facility							(160.7)	(25.3)
Proceeds from stock-based compensation activity							1.3	3
Taxes paid for stock-based compensation activity							(2.4)	(5.7)
Net cash provided by (used in) financing activities:							(540.4)	128.1
Effect of exchange rate changes on cash, cash equivalents and restricted cash							0.3	(0.6)
Net change in cash, cash equivalents and restricted cash							(554.8)	(335.3)
Cash, cash equivalents and restricted cash, beginning of period			642.6			576.3	642.6	576.3
Cash, cash equivalents and restricted cash, end of period	87.8			241			87.8	241
Supplemental disclosure of cash flow information:
Cash paid for interest							56.5	26.7
Cash paid for income taxes							38.3	23.9
Supplemental information on non-cash investing and financing activities:
Purchases of property, plant and equipment unpaid at period end							9.2	10
Reconciliation of cash and cash equivalents and restricted cash:
Cash and cash equivalents	87.8			240.9			87.8	240.9	$ 642.6
Restricted cash				0.1				0.1	0
Total	$ 87.8			241			$ 87.8	241	642.6
Previously Reported
Operating Activities
Net loss		(261.3)	(183)	(75.7)	(56.4)	(3.7)		(135.8)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense								33.4
Depreciation and amortization								107.7
Change in fair value of contingent obligations, net								2.4
Amortization of deferred financing costs								3.1
Deferred income taxes								23
Other								13
Changes in operating assets and liabilities:
Accounts receivable								76.2
Inventories								(112.2)
Prepaid expenses and other assets								(29.2)
Accounts payable								(9)
Accrued expenses and other liabilities								(47.8)
Accrued compensation								(5.7)
Income taxes receivable and payable, net								(50.2)
Contract liabilities								4.2
Net cash used in operating activities								(126.9)
Investing Activities
Purchases of property, plant and equipment								(92.2)
Asset acquisitions								(243.7)
Net cash provided by (used in) investing activities								(335.9)
Financing Activities
Purchases of treasury stock								(81.9)
Proceeds from revolving credit facility								238
Principal payments on term loan facility								(25.3)
Proceeds from stock-based compensation activity								3
Taxes paid for stock-based compensation activity								(5.7)
Net cash provided by (used in) financing activities:								128.1
Effect of exchange rate changes on cash, cash equivalents and restricted cash								(0.6)
Net change in cash, cash equivalents and restricted cash								(335.3)
Cash, cash equivalents and restricted cash, beginning of period						576.3		576.3
Cash, cash equivalents and restricted cash, end of period				241				241
Supplemental disclosure of cash flow information:
Cash paid for interest								26.7
Cash paid for income taxes								23.9
Supplemental information on non-cash investing and financing activities:
Purchases of property, plant and equipment unpaid at period end								10
Reconciliation of cash and cash equivalents and restricted cash:
Cash and cash equivalents				240.9				240.9	642.6
Restricted cash				0.1				0.1	$ 0
Total				241				241
Tax Adjustments
Operating Activities
Net loss		$ (0.1)	(3.7)	(8.1)	7.8	(1.4)		(1.7)
Adjustments to reconcile net loss to net cash used in operating activities:
Deferred income taxes								2.5
Changes in operating assets and liabilities:
Income taxes receivable and payable, net								(0.8)
Other Adjustments
Operating Activities
Net loss			$ 0.5	$ (3.3)	$ (4.3)	$ 0.5		(7.1)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization								(0.1)
Deferred income taxes								0
Changes in operating assets and liabilities:
Accounts receivable								6.3
Inventories								9.4
Prepaid expenses and other assets								(5.1)
Accounts payable								(2.8)
Accrued expenses and other liabilities								$ (0.6)